AngioDynamics (ANGO) 10-Q 9 Jan 15 2015 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Nov. 30, 2014	Jan. 02, 2015
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	30-Nov-14
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q2
Trading Symbol	ANGO
Entity Registrant Name	ANGIODYNAMICS INC
Entity Central Index Key	1275187
Current Fiscal Year End Date	-26
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		35,821,165

Consolidated_Statements_of_Inc

Consolidated Statements of Income (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Nov. 30, 2014	Nov. 30, 2013	Nov. 30, 2014	Nov. 30, 2013
Income Statement [Abstract]
Net sales	$92,149	$88,571	$179,480	$172,215
Cost of sales	44,493	43,686	85,999	84,750
Gross profit	47,656	44,885	93,481	87,465
Operating expenses
Research and development	6,069	7,003	12,787	13,712
Sales and marketing	20,983	21,073	41,050	41,036
General and administrative	7,973	6,411	15,296	12,922
Amortization of intangibles	4,061	4,339	8,076	8,623
Change in fair value of contingent consideration	617	940	1,418	1,673
Acquisition, restructuring and other items, net	2,302	2,679	4,966	4,681
Medical device excise tax	1,076	999	2,071	1,975
Total operating expenses	43,081	43,444	85,664	84,622
Operating income	4,575	1,441	7,817	2,843
Other (expenses) income
Interest expense	-793	-959	-1,592	-2,205
Interest income	1		1	0
Other expense	-954	-832	-1,979	-1,551
Total other expenses, net	-1,746	-1,791	-3,570	-3,756
Income (loss) before income tax expense (benefit)	2,829	-350	4,247	-913
Income tax expense (benefit)	1,491	-89	2,439	-279
Net income (loss)	$1,338	($261)	$1,808	($634)
Income (loss) per share
Basic (in usd per share)	$0.04	($0.01)	$0.05	($0.02)
Diluted (in usd per share)	$0.04	($0.01)	$0.05	($0.02)
Basic weighted average shares outstanding (in shares)	35,595	35,132	35,475	35,041
Diluted weighted average shares outstanding (in shares)	36,127	35,132	36,012	35,041

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Income (USD $)	3 Months Ended		6 Months Ended
	Nov. 30, 2014	Nov. 30, 2013	Nov. 30, 2014	Nov. 30, 2013
Statement of Comprehensive Income [Abstract]
Net Income (Loss)	$1,338,000	($261,000)	$1,808,000	($634,000)
Other comprehensive income (loss), before tax:
Unrealized gain (loss) on interest rate swap	-25,000	-522,000	156,000	-203,000
Unrealized gain (loss) on marketable securities	29,000	0	-112,000	0
Foreign currency translation gain (loss)	-104,000	70,000	-104,000	140,000
Other comprehensive income (loss), before tax	-100,000	-452,000	-60,000	-63,000
Income tax (expense) benefit related to items of other comprehensive income	-1,000	193,000	-16,000	75,000
Other comprehensive income (loss), net of tax	-101,000	-259,000	-76,000	12,000
Total comprehensive income (loss), net of tax	$1,237,000	($520,000)	$1,732,000	($622,000)

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Nov. 30, 2014	31-May-14
In Thousands, unless otherwise specified
CURRENT ASSETS
Cash and cash equivalents	$14,877	$16,105
Marketable securities	1,698	1,809
Accounts receivable, net of allowances of $2,067 and $1,736, respectively	58,556	61,968
Inventories	75,315	61,234
Deferred income taxes	4,091	4,625
Prepaid income taxes	2,156	510
Prepaid expenses and other	6,753	5,471
Total current assets	163,446	151,722
PROPERTY, PLANT AND EQUIPMENT-AT COST, net	67,552	66,590
OTHER ASSETS	2,741	3,926
INTANGIBLE ASSETS, net	197,362	205,256
GOODWILL	360,473	360,473
DEFERRED INCOME TAXES, long term	7,236	10,403
PREPAID ROYALTIES	521	521
TOTAL ASSETS	799,331	798,891
CURRENT LIABILITIES
Accounts payable	21,969	32,895
Accrued liabilities	19,177	16,652
Income Taxes Payable	686	689
Current portion of long-term debt	6,250	5,000
Current portion of contingent consideration	9,795	10,918
Other current liabilities	60	599
Total current liabilities	57,937	66,753
LONG-TERM DEBT, revolving credit facility	61,410	46,410
LONG-TERM DEBT, term loan, net of current portion	87,500	91,250
DEFERRED INCOME TAXES, long term	1,146	1,146
Contingent consideration, net of current portion	47,643	56,413
Other long term liabilities	124	84
Total liabilities	255,760	262,056
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' EQUITY
Preferred stock, par value $.01 per share, 5,000,000 shares authorized; no shares issued and outstanding	0	0
Common stock, par value $.01 per share, 45,000,000 shares authorized; issued and outstanding 35,759,021 and 35,442,004 shares at November 30, 2014 and May 31, 2014, respectively	358	353
Additional paid-in capital	513,353	508,354
Retained earnings	33,309	31,501
Treasury stock, 142,305 shares, at cost	-2,104	-2,104
Accumulated other comprehensive loss	-1,345	-1,269
Total stockholders’ equity	543,571	536,835
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$799,331	$798,891

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Nov. 30, 2014	31-May-14
In Thousands, except Share data, unless otherwise specified
Statement of Financial Position [Abstract]
Accounts receivable, allowances	$1,863	$1,736
Preferred stock, par value	$0.01	$0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$0.01	$0.01
Common stock, shares authorized	45,000,000	45,000,000
Common stock, shares issued	35,646,491	35,060,351
Common stock, shares outstanding	35,646,491	35,060,351
Treasury stock, shares	142,305	142,305

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Nov. 30, 2014	Nov. 30, 2013
Cash flows from operating activities:
Net income (loss)	$1,808	($634)
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	13,999	13,870
Stock based compensation	2,901	2,423
Change in fair value of contingent consideration	1,418	1,673
Deferred income taxes	3,685	1,155
Bad debt expense	345	312
Tax effect on exercise of stock options and issuance of performance shares	0	146
Other	-89	-24
Amortization of acquired inventory basis step-up	0	75
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable	3,069	-123
Inventories	-14,081	-4,351
Prepaid expenses and other assets	-3,712	-1,882
Accounts payable, accrued and other liabilities	-6,138	3,410
Net cash provided by operating activities	3,205	15,758
Cash flows from investing activities:
Additions to property, plant and equipment	-7,523	-7,191
Acquisition of business, net of cash acquired	0	-4,169
Acquisition of intangible	-250	-150
Proceeds from sale or maturity of marketable securities	0	303
Net cash used in investing activities	-7,773	-11,207
Cash flows from financing activities:
Proceeds from issuance of long-term debt	15,000	100,000
Proceeds from borrowings on revolving credit facility	0	41,410
Repayment of long-term debt	-2,500	-143,750
Deferred financing costs on long-term debt	0	677
Payment of contingent consideration previously established in purchase accounting	-11,222	-9,300
Proceeds from exercise of stock options and employee stock purchase plan	2,103	1,133
Net cash provided by (used in) financing activities	3,381	-11,184
Effect of exchange rate changes on cash and cash equivalents	-41	4
Increase (decrease) in cash and cash equivalents	-1,228	-6,629
Cash and cash equivalents at beginning of period	16,105	21,802
Cash and cash equivalents at end of period	14,877
Supplemental disclosure of non-cash investing and financing activities:
Contractual obligations for acquisition of intangibles and business	0	4,970
Contractual obligations for acquisition of fixed assets	$54	$724

Consolidated_Statement_of_Stoc

Consolidated Statement of Stockholders' Equity (USD $)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Loss [Member]	Treasury Stock [Member]
Beginning Balance at May. 31, 2014	$536,835,000	$353,000	$508,354,000	$31,501,000	($1,269,000)	($2,104,000)
Beginning Balance,Treasury Shares at May. 31, 2014	-142,305
Beginning Balance, Shares at May. 31, 2014		35,442,004
Net income (loss)	1,808,000			1,808,000
Exercise of stock options	1,350,000	2,000	1,348,000
Exercise of stock options, Shares		118,334
Purchase of common stock under ESPP	751,000	1,000	750,000
Purchase of common stock under ESPP, Shares		62,574
Issuance of performance shares	2,000	2,000
Issuance of performance shares, Shares		136,109
Stock based compensation	2,901,000		2,901,000
Other comprehensive income, net of tax	-76,000				-76,000
Ending Balance at Nov. 30, 2014	$543,571,000	$358,000	$513,353,000	$33,309,000	($1,345,000)	($2,104,000)
Ending Balance,Treasury Shares at Nov. 30, 2014	-142,305					-142,305
Ending Balance, Shares at Nov. 30, 2014		35,759,021

Consolidated_Financial_Stateme

Consolidated Financial Statements	6 Months Ended
	Nov. 30, 2014
Accounting Policies [Abstract]
Consolidated Financial Statements	CONSOLIDATED FINANCIAL STATEMENTS
	The consolidated balance sheet as of November 30, 2014, the consolidated statement of stockholders’ equity and consolidated statement of cash flows for the six months ended November 30, 2014, the consolidated statements of income and the consolidated statements of comprehensive income for the three and six months ended November 30, 2014 and 2013 have been prepared by us without audit. The consolidated balance sheet as of May 31, 2014 was derived from audited consolidated financial statements but does not include all disclosures required by accounting principles generally accepted in the United States of America. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to state fairly the financial position, changes in stockholders’ equity and comprehensive income, results of operations and cash flows as of and for the period ended November 30, 2014 (and for all periods presented) have been made.
	Certain information and footnote disclosures, normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. It is suggested that these unaudited interim consolidated financial statements be read in conjunction with the financial statements and notes thereto included in the Annual Report on Form 10-K/A for the fiscal year ended May 31, 2014, as revised. Our most significant accounting policies are disclosed in Note A to the consolidated financial statements included in the aforementioned Form 10-K/A for the fiscal year ended May 31, 2014. The results of operations in the fiscal periods ended November 30, 2014 and 2013 are not necessarily indicative of the operating results for the respective full fiscal years.
	The unaudited interim consolidated financial statements for the three and six months ended November 30, 2014 and November 30, 2013 include the accounts of AngioDynamics, Inc. and its wholly owned subsidiaries, collectively, the “Company”. All intercompany balances and transactions have been eliminated.
	During the financial closing process for the first quarter of fiscal year 2015, the Company determined that financial management had incorrectly accounted for certain asset, liability and income statement balances, beginning in 2011. The Company has identified amounts and concluded that they were not material individually or in the aggregate to any of its previously issued annual and interim financial statements. Although management has determined the amounts individually and in the aggregate are not material to prior periods, in accordance with authoritative accounting literature on considering the effects of misstatements in prior years when quantifying misstatements in the current year, the financial statements included herein have been adjusted to correct for the impact of these items. Refer to Note P for further details.

Acquisitions

Acquisitions	6 Months Ended
	Nov. 30, 2014
Business Combinations [Abstract]
Acquisitions	ACQUISITIONS
	Acquisition of Clinical Devices
	On August 15, 2013 we acquired all the outstanding shares of capital stock of Clinical Devices, B.V., exclusive distributor of our fluid management products in the Netherlands. The stock purchase agreement provided for the payment of $3.7 million in cash at closing, which was subject to a working capital adjustment and $400,000 holdback, plus future earn out consideration payable in cash. Earn out consideration was based on our net sales of the fluid management products during the five quarters following the closing as well as milestone payments for achieving regulatory approvals of certain in process research and development for a next-generation tip location technology. The holdback and net sales amounts were paid in September 2014. The total purchase consideration of $8.7 million included the upfront payment and the estimated fair value of contingent consideration at the time of acquisition of $5.0 million.
	Goodwill recorded as a result of the acquisition was approximately $4.8 million and is not deductible for tax purposes. Intangible assets acquired, other than goodwill, totaled approximately $5.1 million, of which $3.6 million has been identified as in-process research and development, $1.4 million as customer relationships (15-year estimated useful life) and $70,000 as trademarks (5-year estimated useful life). We also recorded a deferred tax liability of $1.2 million.
	The acquisition has been accounted for as a purchase and, accordingly, we have included the results of operations in the financial statements effective August 15, 2013. The pro forma effects of the acquisition on our income statement and balance sheet were not material.

Inventories

Inventories	6 Months Ended
	Nov. 30, 2014
Inventory Disclosure [Abstract]
Inventories	INVENTORIES
	Inventories are stated at lower of cost (using the first-in, first-out method) or market. As of November 30, 2014 and May 31, 2014, inventories consisted of the following:
		Nov 30, 2014		31-May-14
				(As revised)
		(in thousands)
	Raw materials	$	30,000	$	24,734
	Work in process	11,774		11,992
	Finished goods	33,541		24,508
	Inventories	$	75,315	$	61,234

Goodwill_and_Intangible_Assets

Goodwill and Intangible Assets	6 Months Ended
	Nov. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	GOODWILL AND INTANGIBLE ASSETS
	Intangible assets other than goodwill and indefinite lived intangible assets are amortized over their estimated useful lives, which range between three and fifteen years, on either a straight-line basis or proportionately to the benefit being realized. We periodically review the estimated useful lives of our intangible assets and review such assets for impairment, based on estimated future cash flows, whenever events or changes in circumstances indicate that the carrying value of the assets may not be recoverable. If an intangible asset is considered to be impaired, the amount of the impairment will equal the excess of the carrying value over the fair value of the asset.
	Goodwill and intangible assets that have indefinite useful lives are not amortized, but rather, are tested for impairment annually or more frequently if impairment indicators arise. Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired in each business combination. Goodwill and intangible assets have been recorded at either incurred or allocated costs based on respective fair market values at the date of acquisition.
	For goodwill, the impairment test requires a comparison of the estimated fair value, based on future cash flows, of the reporting unit to which the goodwill is assigned to the sum of the carrying value of the assets and liabilities of that unit. If the sum of the carrying value of the assets and liabilities of a reporting unit exceeds the fair value of the reporting unit, the carrying value of the reporting unit’s goodwill is reduced to its implied fair value through an adjustment to the goodwill balance, resulting in an impairment charge.
	Adjustments to goodwill for the six months ended November 30, 2014 are as follows (in thousands of dollars):
	Balance, May 31, 2014	$	360,473
		—
	Balance, November 30, 2014	$	360,473
	As of November 30, 2014 and May 31, 2014, intangible assets consisted of the following:
		30-Nov-14
		Gross		Accumulated			Net carrying		Weighted
		carrying		amortization			value		avg useful
		value							life
		(in thousands)							(years)
	Product technologies	$	150,288	$	(37,430	)	$	112,858	10.3
	Customer relationships	86,347		(40,523		)	45,824		12
	Trademark-NAMIC	28,600		—			28,600		Indefinite
	Licenses	7,702		(5,288		)	2,414		8.1
	Trademarks	6,345		(2,279		)	4,066		8
	In-process R&D acquired	3,600		—			3,600		Indefinite
	Distributor relationships	900		(900		)	—		3
		$	283,782	$	(86,420	)	$	197,362
		31-May-14
		Gross		Accumulated			Net carrying		Weighted
		carrying		amortization			value		avg useful
		value							life
		(in thousands)							(years)
	Product technologies	$	150,298	$	(32,930	)	$	117,368	10.2
	Customer relationships	86,645		(37,848		)	48,797		11.9
	Trademark-NAMIC	28,600		—			28,600		Indefinite
	In process R&D acquired	3,600		—			3,600		Indefinite
	Licenses	7,639		(5,211		)	2,428		8.4
	Trademarks	6,345		(1,882		)	4,463		8
	Distributor relationships	900		(900		)	—		3
		$	284,027	$	(78,771	)	$	205,256

Accrued_Liabilities

Accrued Liabilities	6 Months Ended
	Nov. 30, 2014
Payables and Accruals [Abstract]
Accrued Liabilities	ACCRUED LIABILITIES
	As of November 30, 2014 and May 31, 2014, accrued liabilities consisted of the following:
		Nov 30, 2014		31-May-14
				As revised
		(in thousands)
	Payroll and related expenses	$	8,797	$	8,114
	Royalties	2,343		2,620
	Accrued severance	1,020		765
	Sales and franchise taxes	1,398		1,327
	Interest rate swap liability	400		555
	Other	5,219		3,271
	Total	$	19,177	$	16,652

Long_Term_Debt

Long Term Debt	6 Months Ended
	Nov. 30, 2014
Debt Disclosure [Abstract]
Long Term Debt	LONG TERM DEBT
	On September 19, 2013, we entered into a Credit Agreement (the “Credit Agreement”) with the lenders party thereto, JPMorgan Chase Bank, N.A., as administrative agent, Bank of America, N.A. and Keybank National Association as co-syndication agents, and J.P. Morgan Securities LLC, Merrill Lynch, Pierce, Fenner & Smith Incorporated and Keybank National Association as joint bookrunners and joint lead arrangers.
	The Credit Agreement provides for a $100 million senior secured term loan facility (“Term Loan”) and a $100 million senior secured revolving credit facility, which includes up to a $20 million sublimit for letters of credit and a $5 million sublimit for swingline loans (the “Revolving Facility”, and together with the Term Loan, the “Facilities”).
	The proceeds of the Revolving Facility may be used for general corporate purposes of AngioDynamics and its subsidiaries. The Facilities have a five year maturity. The Term Loan has a quarterly repayment schedule equal to 5%, 5%, 10%, 15% and 65% of its principal amount in years one through five. Interest on both the Term Loan and Revolving Facility will be based on a base rate or Eurodollar rate plus an applicable margin which increases as our total leverage ratio increases, with the base rate and Eurodollar rate having ranges of 0.50% to 1.25% and 1.5% to 2.25% respectively. After default, the interest rate may be increased by 2.0%. The Revolving Facility will also carry a commitment fee of 0.2% to 0.35% per annum on the unused portion.
	Our obligations under the Facilities are unconditionally guaranteed, jointly and severally, by our material direct and indirect domestic subsidiaries (the “Guarantors”). All obligations of AngioDynamics and the Guarantors under the Facilities are secured by first priority security interests in substantially all of the assets of AngioDynamics and the Guarantors.
	We have entered into an interest rate swap agreement, (the “Swap Agreement”), with an initial notional amount of $100 million, to limit the effect of rising of interest rates. The Swap Agreement, which qualified for hedge accounting under authoritative guidance, was a contract to exchange floating interest rate payments for fixed interest rate payments on the outstanding balance of the loan over the life of the agreement without the exchange of the underlying notional amounts. The Swap Agreement provides for a fixed rate of 0.74% above the applicable rate provided for in the Credit Agreement.
	On September 19, 2013, we borrowed $100 million under the Term Facility and approximately $41.4 million under the Revolving Facility to repay the Former Credit Agreement. As of November 30, 2014, $93.8 million and $61.4 million were outstanding under the Term Facility and Revolving Facility, respectively. The Credit Agreement includes customary representations, warranties and covenants, and acceleration, indemnity and events of default provisions, including, among other things, two financial covenants. The first financial covenant requires us to maintain, as of the end of each of our fiscal quarters, a ratio of consolidated adjusted EBITDA minus consolidated capital expenditures to consolidated interest expense paid or payable in cash plus scheduled principal payments in respect of indebtedness under the Credit Agreement of not less than 1.35 to 1.00. The second financial covenant requires us to maintain, as of the end of each of our fiscal quarters, a ratio of consolidated total indebtedness to consolidated adjusted EBITDA of not greater than 3.75 to 1.00. We were in compliance with both covenants as of November 30, 2014.

Income_Taxes

Income Taxes	6 Months Ended
	Nov. 30, 2014
Income Tax Disclosure [Abstract]
Income Taxes	G - INCOME TAXES
	The following table presents the components of income tax expense(benefit) for the three and six months ended November 30, 2014 and 2013 (in thousands of dollars):
		Three Months Ended		Six Months Ended
		Nov 30, 2014	Nov 30, 2013	Nov 30, 2014	Nov 30, 2013
			(As revised)		(As revised)
	Income tax expense (benefit) based on income (loss) from continuing operations at estimated tax rates of 40.9% and 38.8% for the three and six months ended November 30, 2014 and 2013, respectively	$1,140	($150)	$1,738	($354)
	Discrete tax expense (benefit):
	Adjustment for elimination of the ASC 718 APIC pool	330	61	685	61
	Adjustments to prior period tax liabilities	21	—	16	14
	Total income tax expense (benefit)	$1,491	($89)	$2,439	($279)
	The second quarter estimated effective tax rate prior to discrete items was 40.9% in 2014, as compared to 38.8% for the same period in 2013.
	Our ASC 718 APIC pool was depleted in the quarter ended November 30, 2014. Prior to its depletion, the APIC pool was reduced when share-based compensation cost previously recognized by us was greater than the deduction allowed for income tax purposes based on the price of our common stock on the date of exercise or vesting. Due to its depletion we recorded a discrete tax expense of $330 thousand and $61 thousand in the second quarters of fiscal 2015 and 2014, respectively.
	We currently believe that we will generate taxable income in the future sufficient to realize the benefit of all of our deferred tax assets which consisted primarily of net operating loss carry forwards recorded in business acquisitions. However, some or all of these deferred tax assets could expire unused if we are unable to generate taxable income in the future sufficient to utilize them. We will need to generate $10.0 million of taxable income each year from 2015 to 2023 and then $6.5 million per year until 2033 in order to utilize all of our net operating loss carry forwards. If it becomes more likely than not that our deferred tax assets will expire unused, a valuation allowance will be recorded, which may significantly increase our income tax expense, and therefore adversely affect our results of operations in the period in which it is recorded.
	During the fiscal third quarter of 2014, The Tax Increase Prevention Act of 2014 (H.R. 5771) was enacted and retroactively extended the research credit from January 1, 2014 to December 31, 2014. Accordingly, the retroactive benefit related to this renewal will be reflected in our third quarter results.

ShareBased_Compensation

Share-Based Compensation	6 Months Ended
	Nov. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-Based Compensation	SHARE-BASED COMPENSATION
	We have two stock-based compensation plans that provide for the issuance of up to approximately 5.8 million shares of common stock. The 2004 Stock and Incentive Award Plan (the "2004 Plan") provides for the grant of incentive options to our employees and for the grant of non-statutory stock options, restricted stock, stock appreciation rights, performance units, performance shares and other incentive awards to our employees, directors and other service providers. We also have an employee stock purchase plan.
	For the quarters ended November 30, 2014 and 2013, share-based payment expense was $1.5 million and $1.3 million, respectively.
	In the second quarter of fiscal year 2015 and 2014, the company granted stock options and restricted stock units under the 2004 Plan to certain employees and members of the Board of Directors. Stock option awards are valued using the Black-Scholes option-pricing model and then amortized on a straight-line basis over the requisite service period of the award. Restricted stock unit awards are valued based on the closing trading value of our shares on the date of grant and then amortized on a straight-line basis over the requisite service period of the award.
	In the first quarter of fiscal year 2015 and the second quarter of 2014, the company granted performance share awards under the 2004 Plan to certain employees. The awards may be earned by achieving relative performance levels over the three year requisite service period. The performance criteria are based on the total shareholder return ("TSR") of the company's common stock relative to the TSR of the common stock of a pre-defined industry peer-group. The fair value of these awards are based on the closing trading value of our shares on the date of grant and use a Monte Carlo simulation model.
	As of November 30, 2014, there were $13.3 million of unrecognized compensation expenses related to share-based payment arrangements. These costs are expected to be recognized over a weighted-average period of approximately four years. The company has sufficient shares to satisfy expected share-based payment arrangements.

Earnings_Per_Share

Earnings Per Share	6 Months Ended
	Nov. 30, 2014
Earnings Per Share [Abstract]
Earnings Per Share	EARNINGS PER SHARE
	Basic earnings per share are based on the weighted average number of common shares outstanding without consideration of potential common stock. In addition, diluted earnings per share include the dilutive effect of potential common stock consisting of stock options, restricted stock units and performance stock units, provided that the inclusion of such securities is not antidilutive. In periods with a net loss, stock options and restricted stock units are not included in the computation of basic loss per share as the impact would be anti-dilutive.
	The following table reconciles basic to diluted weighted-average shares outstanding for the three and six months ended November 30, 2014 and 2013 (in thousands):
		Three Months Ended		Six Months Ended
		Nov 30, 2014	Nov 30, 2013	Nov 30, 2014	Nov 30, 2013
	Basic	35,595	35,132	35,475	35,041
	Effect of dilutive securities	532	—	537	—
	Diluted	36,127	35,132	36,012	35,041
	Excluded from the calculation of diluted earnings per common share are stock options issued to employees and non-employees to purchase 0.8 million shares and 0.9 million shares of common stock for the three and six months ended November 30, 2014, respectively, as their inclusion would be antidilutive. For the three and six months ended November 30, 2013 options and restricted stock awards issued to employees and non-employees to purchase 2.3 million shares and 2.7 million shares of common stock, respectively, were also excluded as their inclusion would have been antidilutive.

Segment_and_Geographic_Informa

Segment and Geographic Information	6 Months Ended
	Nov. 30, 2014
Segment Reporting [Abstract]
Segment and Geographic Information	SEGMENT AND GEOGRAPHIC INFORMATION
	We consider our business to be a single operating segment entity engaged in the development, manufacture and sale on a global basis of medical devices for vascular access, surgery, peripheral vascular disease and oncology. Our chief operating decision maker (CEO) evaluates the various global product portfolios on a net sales basis. Executives reporting to the CEO include those responsible for operations and supply chain management, research and development, sales, franchise marketing and certain corporate functions. The CEO evaluates profitability, investment and cash flow metrics on a consolidated worldwide basis due to shared infrastructure and resources.
	The table below summarizes net sales by product category (in thousands of dollars):
		Three Months Ended				Six Months Ended
		Nov 30, 2014		Nov 30, 2013		Nov 30, 2014		Nov 30, 2013
				As revised				As revised
	Net sales
	Peripheral Vascular	$	49,440	$	48,815	$	96,801	$	94,360
	Vascular Access	27,968		25,571		54,393		50,854
	Oncology/Surgery	13,634		12,557		25,996		23,724
	Supply Agreement	1,107		1,628		2,290		3,277
	Total	$	92,149	$	88,571	$	179,480	$	172,215
	The table below presents net sales by geographic area based on external customer location (in thousands of dollars):
		Three Months Ended				Six Months Ended
		Nov 30, 2014		Nov 30, 2013		Nov 30, 2014		Nov 30, 2013
				As revised				As revised
	Net sales
	United States	$	72,058	$	69,485	$	140,438	$	136,652
	International	18,984		17,458		36,752		32,286
	Supply Agreement	1,107		1,628		2,290		3,277
	Total	$	92,149	$	88,571	$	179,480	$	172,215

Fair_Value

Fair Value	6 Months Ended
	Nov. 30, 2014
Fair Value Disclosures [Abstract]
Fair Value	FAIR VALUE
	Our financial instruments include cash and cash equivalents, accounts receivable, marketable securities, accounts payable, interest rate swap agreement and contingent earn outs. The carrying amount of cash and cash equivalents, accounts receivable, marketable securities and accounts payable approximates fair value due to the immediate or short-term maturities. The interest rate swap agreement has been recorded at its fair value based on a valuation received from an independent third party. The contingent earn out has been recorded at fair value using the income approach.
	Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. This policy establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The policy describes three levels of inputs that may be used to measure fair value which are provided in the table below.
	Level 1 Quoted prices in active markets for identical assets or liabilities. Level 1 assets include bank time deposits, money market funds, mutual funds and U.S. Treasury securities that are traded in an active exchange market.
	Level 2 Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 2 assets include US government securities and corporate bonds. When quoted market prices are unobservable, we obtain pricing information from an independent pricing vendor. The pricing vendor uses various pricing models for each asset class that are consistent with what other market participants would use. The inputs and assumptions to the model of the pricing vendor are derived from market observable sources including: benchmark yields, reported trades, broker/dealer quotes, issuer spreads, benchmark securities, bids, offers, and other market-related data. Since many fixed income securities do not trade on a daily basis, the methodology of the pricing vendor uses available information as applicable such as benchmark curves, benchmarking of like securities, sector groupings, and matrix pricing. The pricing vendor considers all available market observable inputs in determining the evaluation for a security. Thus, certain securities may not be priced using quoted prices, but rather determined from market observable information. These investments are included in Level 2 and primarily comprise our portfolio of corporate and government fixed income securities. Additionally included in Level 2 are interest rate swap agreements which are valued using a mid-market valuation model.
	Level 3 Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation. This category currently includes the auction rate securities where independent pricing information was not able to be obtained and the contingent earn out. Our investments in auction-rate securities were classified as Level 3 as quoted prices were unavailable since these auction rate securities issued by New York state and local government authorities failed auction. Due to limited market information, we utilized a discounted cash flow (“DCF”) model to derive an estimate of fair value for all periods presented. The assumptions used in preparing the DCF model included estimates with respect to the amount and timing of future interest and principal payments, forward projections of the interest rate benchmarks, the probability of full repayment of the principal considering the credit quality and guarantees in place, and the rate of return required by investors to own such securities given the current liquidity risk associated with auction-rate securities. The contingent earn outs were valued utilizing a discounted cash flow method as detailed below.
	The following tables provide information by level for assets and liabilities that are measured at fair value on a recurring basis as of November 30, 2014 and May 31, 2014 (in thousands of dollars):
		Fair Value Measurements using									Fair Value at November 30, 2014
		inputs considered as:
		Level 1				Level 2			Level 3
	Financial Assets
	Cash equivalents
	Money market funds	$	1			$	—		$	—	$	1
	Total	$	1			$	—		$	—	$	1
	Marketable securities
	U.S. government agency obligations	$	—			$	—		$	1,698	$	1,698
	Total	—				—			1,698		1,698
	Total Financial Assets	$	1			$	—		$	1,698	$	1,699
	Financial Liabilities
	Interest rate swap agreements	$	—			$	400		$	—	$	400
	Contingent liability for acquisition earn out	—				—			57,438		57,438
	Total Financial Liabilities	$	—			$	400		$	57,438	$	57,838
		Fair Value Measurements using									Fair Value at May 31, 2014
		inputs considered as:
		Level 1				Level 2			Level 3
	Financial Assets								As revised		As revised
	Cash equivalents
	Money market funds	$	445			$	—		$	—	$	445
	Total	$	445			$	—		$	—	$	445
	Marketable securities
	U.S. government agency obligations	$	—			$	—		$	1,809	$	1,809
	Total	—				—			1,809		1,809
	Total Financial Assets	$	445			$	—		$	1,809	$	2,254
	Financial Liabilities
	Interest rate swap agreements	$	—			$	555		$	—	$	555
	Contingent liability for acquisition earn out	—				—			67,331		67,331
	Total Financial Liabilities	$	—			$	555		$	67,331	$	67,886
	There were no transfers in and out of Level 1, 2 and 3 measurements for the six months ended November 30, 2014.
	The table below presents the components of Level 3 fair value instruments as of November 30, 2014 (in thousands of dollars):
		Financial Assets				Financial Liabilities
		Fair Value Measurements				Fair Value Measurements
		Using Significant				Using Significant
		Unobservable Inputs				Unobservable Inputs
		(Level 3)				(Level 3)
						As revised
	Balance, May 31, 2014	$	1,809			$	67,331
	Earnings revaluation expense - included in earnings	—				1,418
	Currency (gain) loss	—				(89		)
	Included in other comprehensive income	(111		)		—
	Contingent consideration - Microsulis	—				(11,222		)
	Balance, November 30, 2014	$	1,698			$	57,438
	Contingent Liabilities for Acquisition Earn Outs
	Certain of our business combinations involve the potential for the payment of future contingent consideration upon the achievement of certain product development milestones or various other performance conditions. Payment of the additional consideration is generally contingent on the acquired company reaching certain performance milestones, including attaining specified revenue levels or product development targets. Contingent consideration is recorded at the estimated fair value of the contingent payments on the acquisition date. The fair value of the contingent milestone consideration is remeasured at the estimated fair value at each reporting period with the change in fair value recognized as income or expense within change in fair value of contingent consideration in the consolidated statements of income. We measure the initial liability and remeasure the liability on a recurring basis using Level 3 inputs as defined under authoritative guidance for fair value measurements.
	Contingent consideration liabilities fair value is determined using a discounted cash flow model applied to projected net sales, using probabilities of payment and projected payment dates. Projected net sales are based on our internal projections and extensive analysis of the target market and the sales potential. Increases or decreases in any valuation inputs in isolation may result in a significantly lower or higher fair value measurement in the future.
	The recurring Level 3 fair value measurements of the contingent consideration liabilities include the following significant unobservable inputs as of November 30, 2014 (in thousands of dollars):
		Fair value at				Valuation
		Nov 30, 2014				Technique		Unobservable Input	Range
	Revenue based payments	$	54,160			Discounted cash flow		Discount rate	4%-10%
								Probability of payment	75-100%
								Projected fiscal year of payment	2016 - 2022
	Milestone based payments	3,278				Discounted cash flow		Discount rate	16%-20%
								Probability of payment	75-100%
								Projected fiscal year of payment	2017
	Total	$	57,438
At November 30, 2014, the estimated potential amount of undiscounted future contingent consideration that we expect to pay as a result of all completed acquisitions is approximately $67.7 million. The milestones associated with the contingent consideration must be reached in future periods ranging from fiscal years 2016 to 2022 in order for the associated consideration to be paid.
The fair value of contingent milestone payments associated with the acquisitions was analyzed as of November 30, 2014 and $47.6 million was reflected in “Contingent consideration, net of current portion” and $9.8 million was reflected in “Current portion of contingent consideration” on the consolidated balance sheet.
The following table provides a reconciliation of the beginning and ending balances of contingent milestone payments measured at fair value that used significant unobservable inputs (Level 3) (in thousands of dollars):
			Total Contingent Consideration
			As revised
Beginning balance -	31-May-14		$	67,331
Contingent payments			(11,222		)
Earnings revaluation expense			1,418
Currency (gain) loss			(89		)
Ending balance -	30-Nov-14		$	57,438

Marketable_Securities

Marketable Securities	6 Months Ended
	Nov. 30, 2014
Investments, Debt and Equity Securities [Abstract]
Marketable Securities	MARKETABLE SECURITIES
	Marketable securities, which are principally government agency bonds, auction rate investments and corporate commercial paper, are classified as “available-for-sale securities” in accordance with authoritative guidance issued by FASB and are reported at fair value, with unrealized gains and losses excluded from operations and reported as accumulated other comprehensive income (loss), net of the related tax effects, in stockholders’ equity. Cost is determined using the specific identification method. We hold investments in auction rate securities in order to generate higher than typical money market rate investment returns. Auction rate securities typically are high credit quality, generally achieved with municipal bond insurance. Credit risks are eased by the historical track record of bond insurers, which back a majority of this market. Sell orders for any security traded through an auction process could exceed bids and, in such cases, the auction fails and we may be unable to liquidate our position in the securities in the near term. As of November 30, 2014 and May 31, 2014, we had $1.7 million and $1.8 million, respectively, in investments in two auction rate securities issued by New York state and local government authorities that failed auctions. The authorities are current in their interest payments on the securities.
	As of November 30, 2014 and May 31, 2014, marketable securities consisted of the following (in thousands of dollars):
	As of November 30, 2014	Amortized		Gross		Gross			Fair Value
		cost		Unrealized		Unrealized
				Gains		Losses
	Available-for-sales securities
	U.S. government agency obligations	$	1,825	$	—	$	(127	)	$	1,698
		$	1,825	$	—	$	(127	)	$	1,698
	As of May 31, 2014	Amortized		Gross		Gross			Fair Value
		cost		Unrealized		Unrealized
				Gains		Losses
	Available-for-sales securities
	U.S. government agency obligations	$	1,825	$	—	$	(16	)	$	1,809
		$	1,825	$	—	$	(16	)	$	1,809

Commitments_and_Contingencies

Commitments and Contingencies	6 Months Ended
	Nov. 30, 2014
Commitments and Contingencies Disclosure [Abstract]
Litigation	COMMITMENTS AND CONTINGENCIES
	Legal Proceedings
	The Company is involved in various legal proceedings, including commercial, intellectual property, product liability, regulatory and environmental matters of a nature considered normal for its business. The Company accrues for amounts related to these matters if it is probable that a liability has been incurred, and an amount can be reasonably estimated. The Company discloses such matters when there is at least a reasonable possibility that a material loss may have been incurred. However, the Company cannot predict the outcome of any litigation or the potential for future litigation.
	AngioDynamics v. biolitec
	On January 2, 2008, we commenced an action in the United States District Court for the Northern District of New York entitled AngioDynamics, Inc. v. biolitec, Inc. In this action, we sought judgment against biolitec for defense and indemnification in two lawsuits which we previously settled. Our claims arise out of a Supply and Distribution Agreement (“SDA”) entered into with biolitec on April 1, 2002. On September 27, 2011, the U.S. District Court granted key portions of our motion for summary judgment in our legal case against biolitec. The Court also dismissed biolitec’s counterclaims against us. The court denied one portion of our summary judgment motion, which sought to recover additional costs from biolitec, leaving this for adjudication at trial. On November 8, 2012, the Court granted partial judgment to us in the amount of $23.2 million. Biolitec appealed this judgment. On August 23, 2013, the U.S. Court of Appeals for the Second Circuit dismissed biolitec’s appeal.
	In October 2009, we commenced an action in the United States District Court for the District of Massachusetts entitled AngioDynamics, Inc. v. biolitec AG and Wolfgang Neuberger. The Complaint in this action was amended in March 2010. This action seeks to recover against biolitec, Inc.’s parent entities and CEO for tortuously interfering with biolitec, Inc.’s contractual obligation to defend and indemnify us, and also seeks to pierce the corporate veil of biolitec, Inc. and to invalidate certain alleged fraudulent transfers in order to hold biolitec, Inc.’s parent entities jointly and severally liable for the alleged breach of the SDA. On September 13, 2012, the Massachusetts Court granted our request for a preliminary injunction prohibiting the downstream merger of biolitec AG with its Austrian subsidiary. On April 1, 2013, the U.S. Court of Appeals for the First Circuit affirmed the preliminary injunction. On January 14, 2014, the District Court entered judgment in our favor as to liability. On March 18, 2014, the District Court entered judgment in our favor against Biolitec AG, Biomed Technology Holdings, Ltd., and Wolfgang Neuberger, jointly and severally, in the amount of $74.9 million. The defendants have appealed this judgment.
	August 29, 2013, we became co-plaintiffs in an adversary proceeding in the United States Bankruptcy Court for the District of New Jersey entitled Cyganowski, Trustee, et al. v. Biolitec U.S., Inc., et al. In this action, we assert claims of conversion, unjust enrichment, tortious interference, and unfair competition against various biolitec entities for alleged violation of Bankruptcy Court settlement and sale orders under which we acquired certain assets of Biolitec, Inc. On September 3, 2013, we, along with our co-plaintiff, obtained a temporary restraining order against the defendants in this action. The restraining order is still in place and the Bankruptcy Court is currently considering our request for permanent injunctive relief.
	C.R. Bard, Inc. v. AngioDynamics, Inc.
	On January 11, 2012, C.R. Bard, Inc. filed a suit in the United States District Court of Utah claiming certain of our implantable port products infringe on patents held by Bard. Bard is seeking unspecified damages and other relief. The Court denied Bard’s motion for pre-trial consolidation with separate actions it filed on the same day against Medical Components, Inc. and Smiths Medical ASD, Inc., but had asked for supplemental briefing on the issue of whether to conduct a common Markman hearing. Meanwhile, we filed petitions for reexamination in the US Patent and Trademark Office ("PTO") which seek to invalidate all three patents asserted in the litigation. Our petitions have been granted and 40 of 41 patent claims have been and remain rejected. The Patent Office has issued a Final Rejection of all the claims subject to reexamination and Bard has filed appeals. The parties are currently in the midst of the briefing process for these appeals. The case has been stayed pending final resolution of the PTO process. We believe these claims are without merit and intend to defend them vigorously. We have not recorded an expense related to the outcome of this litigation because it is not yet possible to determine if a potential loss is probable nor reasonably estimable.
	BTG International, Inc.
	We received a subpoena from the U.S. Department of Justice (the “DOJ”) requesting documents in relation to a purported criminal investigation the DOJ is conducting regarding BTG International, Inc.’s LC Bead® product beginning in 2003.  RITA Medical Systems and AngioDynamics, Inc., after its acquisition of RITA, was the exclusive distributor of LC Beads in the United States from 2006 through December 31, 2011.  We are cooperating fully with this investigation and at this time are unable to predict its scope, duration or outcome.
	EndoVention v. AngioDynamics
	On November 21, 2014, EndoVention, Inc. filed a complaint in the United States District Court for the Northern District of California, alleging that our AngioVac products infringe two of EndoVention’s patents.  The complaint has not been served.   We believe these allegations are without merit and we intend to defend them vigorously.
	Regulatory Matter
	On November 5, 2014, the Company received a Warning Letter from the FDA relating to observations noted during FDA’s inspection of the Company’s Navilyst Medical facilities located in Marlborough, Massachusetts and Glens Falls, New York in 2014.  The matters raised in the Warning Letter and observations focused on design control processes related to packaging validations and accelerated and real time aging testing in connection with the Company’s fluid management and PICC families of products, inconsistency of a manufacturing product test process used among similar valved PICC products, a particular verification test of valved PICC products and non-conforming product control procedures.  The Company takes these matters seriously and is committed to complying with all applicable laws, regulations and rules in connection with the manufacturing, sale and marketing of its products.  The Company intends to make a comprehensive response to the issues raised in the letter and is committed to working with FDA to resolve all outstanding issues. The Company does not expect this matter will have a material adverse effect on its financial position or results of operations.

Recently_Issued_Accounting_Pro

Recently Issued Accounting Pronouncements	6 Months Ended
	Nov. 30, 2014
Accounting Changes and Error Corrections [Abstract]
Recently Issued Accounting Pronouncements	RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS
	In May 2014, the FASB and the International Accounting Standards Board (“IASB”) issued their final standard on revenue from contracts with customers. The standard, issued as an ASU by the FASB and as International Financial Reporting Standards 15 by the IASB, outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The core principle of the revenue model is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This ASU is effective for the Company in its first quarter beginning January 1, 2017 and is not expected to have a material impact on the Company’s consolidated financial statements.
	In June 2014, the FASB issued an ASU that clarified that entities should treat performance targets that can be met after the requisite service period of a share-based payment award as performance conditions that affect vesting. Therefore, an entity would not record compensation expense related to an award for which transfer to the employee is contingent on the entity’s satisfaction of a performance target until it becomes probable that the performance target is met. This ASU is effective for the Company in its first quarter beginning January 1, 2016 and is not expected to have a material impact on the Company’s consolidated financial statements.

Restructuring

Restructuring	6 Months Ended
	Nov. 30, 2014
Restructuring and Related Activities [Abstract]
Restructuring	RESTRUCTURING
	During the three and six months ended November 30, 2014 we initiated a restructuring of finance, R&D and S&M organizations to improve our profitability. As part of the restructuring, we recorded $0.1 million and $1.1 million of severance expense, respectively, which is included in “Acquisition, restructuring and other items, net” in the statements of income.

Immaterial_Corrections

Immaterial Corrections	6 Months Ended
	Nov. 30, 2014
Accounting Changes and Error Corrections [Abstract]
Immaterial Corrections	IMMATERIAL ERROR CORRECTIONS
	During the financial closing process for the first quarter of fiscal year 2015, the Company determined that financial management had incorrectly accounted for certain asset, liability and income statement balances, beginning in 2011. The Company has identified amounts and concluded that they were not material individually or in the aggregate to any of its previously issued annual and interim financial statements. Although management has determined the amounts individually and in the aggregate are not material to prior periods, in accordance with authoritative accounting literature on considering the effects of misstatements in prior years when quantifying misstatements in the current year, the financial statements included herein have been adjusted to correct for the impact of these items.
	The Company has corrected the relevant financial information from previous reporting periods contained in these financial statements. The immaterial error corrections identified were primarily related to our failure to recognize the expense associated with prepaid and other assets in accordance with the underlying contractual terms (cumulative impact of approximately $1.2 million) and depreciation expense (cumulative impact of approximately $0.4 million), and other individually immaterial items. Also, approximately $5.4 million of contingent consideration liabilities that had been classified as current are classified as long term in the balance sheet.
	The impacts of these revisions are shown in the tables below:
		Three months ended August 31, 2013
		As previously reported			Adjustments			As revised
	Net sales	$	83,579		$	65		$	83,644
	Cost of sales	41,097			(33		)	41,064
	Gross profit	42,482			98			42,580
	Total operating expenses	41,195			(17		)	41,178
	Operating income	1,287			115			1,402
	Total other income (expenses)	(1,934		)	(31		)	(1,965		)
	Income (loss) before taxes	(647		)	84			(563		)
	Income tax benefit (expense)	221			(31		)	190
	Net income (loss)	(426		)	53			(373		)
	Total comprehensive income (loss), net of tax	(155		)	53			(102		)
		Three months ended November 30, 2013
		As previously reported			Adjustments			As revised
	Net sales	$	88,616		$	(45	)	$	88,571
	Cost of sales	43,686			—			43,686
	Gross profit	44,930			(45		)	44,885
	Total operating expenses	43,356			88			43,444
	Operating income	1,574			(133		)	1,441
	Total other income (expense)	(1,660		)	(131		)	(1,791		)
	Income (loss) before taxes	(86		)	(264		)	(350		)
	Income tax benefit (expense)	(13		)	102			89
	Net income (loss)	(99		)	(162		)	(261		)
	Total comprehensive income (loss), net of tax	(358		)	(162		)	(520		)
		Six months ended November 30, 2013
		As previously reported			Adjustments			As revised
	Net sales	$	172,195		$	20		$	172,215
	Cost of sales	84,783			(33		)	84,750
	Gross profit	87,412			53			87,465
	Total operating expenses	84,551			71			84,622
	Operating income	2,861			(18		)	2,843
	Total other income (expense)	(3,594		)	(162		)	(3,756		)
	Income (loss) before taxes	(733		)	(180		)	(913		)
	Income tax benefit (expense)	208			71			279
	Net income (loss)	(525		)	(109		)	(634		)
	Total comprehensive income (loss), net of tax	(513		)	(109		)	(622		)
		Three months ended February 28, 2014
		As previously reported			Adjustments			As revised
	Net sales	$	88,195		$	(45	)	$	88,150
	Cost of sales	43,277			80			43,357
	Gross profit	44,918			(125		)	44,793
	Total operating expenses	38,066			214			38,280
	Operating income	6,852			(339		)	6,513
	Total other income (expense)	(1,985		)	15			(1,970		)
	Income (loss) before taxes	4,867			(324		)	4,543
	Income tax benefit (expense)	(176		)	148			(28		)
	Net income (loss)	4,691			(176		)	4,515
	Total comprehensive income (loss), net of tax	4,869			(176		)	4,693
		Nine months ended February 28, 2014
		As previously reported			Adjustments			As revised
	Net sales	$	260,390		$	(25	)	$	260,365
	Cost of sales	128,060			47			128,107
	Gross profit	132,330			(72		)	132,258
	Total operating expenses	122,617			285			122,902
	Operating income	9,713			(357		)	9,356
	Total other income (expense)	(5,579		)	(147		)	(5,726		)
	Income (loss) before taxes	4,134			(504		)	3,630
	Income tax benefit (expense)	32			219			251
	Net income (loss)	4,166			(285		)	3,881
	Total comprehensive income (loss), net of tax	4,356			(285		)	4,071
	Three months ended May 31, 2014
	As previously reported			Adjustments			As revised
Net sales	$	94,065		$	(5	)	$	94,060
Cost of sales	46,534			116			46,650
Gross profit	47,531			(121		)	47,410
Total operating expenses	43,796			30			43,826
Operating income	3,735			(151		)	3,584
Total other income (expense)	(1,489		)	15			(1,474		)
Income (loss) before taxes	2,246			(136		)	2,110
Income tax benefit (expense)	(3,324		)	(1		)	(3,325		)
Net income (loss)	(1,078		)	(137		)	(1,215		)
Total comprehensive income (loss), net of tax	(1,003		)	(137		)	(1,140		)
	Year ended May 31, 2014
	As previously reported			Adjustments			As revised
Net sales	$	354,455		$	(30	)	$	354,425
Cost of sales	174,594			163			174,757
Gross profit	179,861			(193		)	179,668
Total operating expenses	166,413			315			166,728
Operating income	13,448			(508		)	12,940
Total other income (expense)	(7,068		)	(132		)	(7,200		)
Income (loss) before taxes	6,380			(640		)	5,740
Income tax benefit (expense)	(3,292		)	218			(3,074		)
Net income (loss)	3,088			(422		)	2,666
Total comprehensive income (loss), net of tax	3.353			(422		)	2.931
	Year ended May 31, 2014
	As previously reported			Adjustments			As revised
Net cash provided by (used in) operating activities	$	25,280		$	(599	)	$	24,681
Net cash provided by (used in) investing activities	(17,047		)	599			(16,448		)
Net cash provided by (used in) financing activities	(14,016		)	—			(14,016		)
	As of May 31, 2014
	As previously reported			Adjustments			As revised
Accounts receivable, net of allowances	$	62,148		$	(180	)	$	61,968
Inventories	61,056			178			61,234
Prepaid expenses and other	5,975			(504		)	5,471
Total current assets	152,228			(506		)	151,722
Property, plant and equipment, net	67,208			(618		)	66,590
Other assets	4,876			(950		)	3,926
Goodwill	360,294			179			360,473
Deferred income taxes, long term	9,767			636			10,403
Total assets	800,150			(1,259		)	798,891
Accrued liabilities	16,762			(110		)	16,652
Current portion of contingent payments	16,341			(5,423		)	10,918
Total current liabilities	72,286			(5,533		)	66,753
Contingent consideration, net of current portion	51,080			5,333			56,413
Total liabilities	262,256			(200		)	262,056
Additional paid-in capital	508,263			91			508,354
Retained earnings	32,651			(1,150		)	31,501
Total stockholders' equity	537,894			(1,059		)	536,835
	Year ended May 31, 2013
	As previously reported			Adjustments			As revised
Net sales	$	342,026		$	(110	)	$	341,916
Cost of sales	173,037			365			173,402
Gross profit	168,989			(475		)	168,514
Total operating expenses	161,895			331			162,226
Operating income	7,094			(806		)	6,288
Total other income (expense)	(7,737		)	(138		)	(7,875		)
Income (loss) before taxes	(643		)	(944		)	(1,587		)
Income tax benefit (expense)	31			345			376
Net income (loss)	(612		)	(599		)	(1,211		)
Total comprehensive income (loss), net of tax	(872		)	(599		)	(1,471		)
	Year ended May 31, 2013
	As previously reported			Adjustments			As revised
Net cash provided by (used in) operating activities	$	26,883		$	(231	)	$	26,652
Net cash provided by (used in) investing activities	(22,238		)	—			(22,238		)
Net cash provided by (used in) financing activities	(6,286		)	—			(6,286		)
	As of May 31, 2013
	As previously reported			Adjustments			As revised
Accounts receivable, net of allowances	$	47,791		$	(110	)	$	47,681
Inventories	55,062			17			55,079
Prepaid expenses and other	7,554			(269		)	7,285
Total current assets	141,516			(362		)	141,154
Property, plant and equipment, net	62,650			(259		)	62,391
Other assets	5,559			(651		)	4,908
Intangible assets, net	214,848			(175		)	214,673
Goodwill	355,458			179			355,637
Deferred income taxes, long term	11,007			418			11,425
Total assets	791,584			(850		)	790,734
Accounts payable	24,522			(52		)	24,470
Accrued liabilities	16,426			(70		)	16,356
Total current liabilities	63,437			(122		)	63,315
Total liabilities	264,754			(122		)	264,632
Retained earnings	29,563			(728		)	28,835
Total stockholders' equity	526,830			(728		)	526,102
	Year ended May 31, 2012
	As previously reported			Adjustments			As revised
Net sales	$	221,787		$	130		$	221,917
Cost of sales	95,829			779			96,608
Gross profit	125,958			(649		)	125,309
Total operating expenses	128,920			297			129,217
Operating income	(2,962		)	(946		)	(3,908		)
Total other income (expense)	(2,320		)	806			(1,514		)
Income (loss) before taxes	(5,282		)	(140		)	(5,422		)
Income tax expense (benefit)	188			51			239
Net income (loss)	(5,094		)	(89		)	(5,183		)
Total comprehensive income (loss), net of tax	(5,095		)	(89		)	(5,184		)
	Year ended May 31, 2012
	As previously reported			Adjustments			As revised
Net cash provided by (used in) operating activities	$	11,497		$	105		$	11,602
Net cash provided by (used in) investing activities	(176,360		)	126			(176,234		)
Net cash provided by (used in) financing activities	142,338			—			142,338
	As of May 31, 2012
	As previously reported			Adjustments			As revised
Cash and cash equivalents	$	23,508		$	231		$	23,739
Accounts receivable, net of allowances	48,588			(1,685		)	46,903
Prepaid expenses and other	9,826			(23		)	9,803
Total current assets	159,238			(1,477		)	157,761
Property, plant and equipment, net	55,915			(305		)	55,610
Other assets	10,707			(348		)	10,359
Intangible assets, net	147,266			97			147,363
Goodwill	308,912			179			309,091
Deferred income taxes, long term	39,198			73			39,271
Total assets	721,769			(1,781		)	719,988
Accrued liabilities	18,722			(1,652		)	17,070
Total current liabilities	55,422			(1,652		)	53,770
Total liabilities	198,249			(1,652		)	196,597
Retained earnings	30,175			(129		)	30,046
Total stockholders' equity	523,520			(129		)	523,391

Inventories_Tables

Inventories (Tables)	6 Months Ended
	Nov. 30, 2014
Inventory Disclosure [Abstract]
Schedule of Inventories	Inventories are stated at lower of cost (using the first-in, first-out method) or market. As of November 30, 2014 and May 31, 2014, inventories consisted of the following:
		Nov 30, 2014		31-May-14
				(As revised)
		(in thousands)
	Raw materials	$	30,000	$	24,734
	Work in process	11,774		11,992
	Finished goods	33,541		24,508
	Inventories	$	75,315	$	61,234

Goodwill_and_Intangible_Assets1

Goodwill and Intangible Assets (Tables)	6 Months Ended
	Nov. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill by Segment	Adjustments to goodwill for the six months ended November 30, 2014 are as follows (in thousands of dollars):
	Balance, May 31, 2014	$	360,473
		—
	Balance, November 30, 2014	$	360,473
Intangible Assets	As of November 30, 2014 and May 31, 2014, intangible assets consisted of the following:
		30-Nov-14
		Gross		Accumulated			Net carrying		Weighted
		carrying		amortization			value		avg useful
		value							life
		(in thousands)							(years)
	Product technologies	$	150,288	$	(37,430	)	$	112,858	10.3
	Customer relationships	86,347		(40,523		)	45,824		12
	Trademark-NAMIC	28,600		—			28,600		Indefinite
	Licenses	7,702		(5,288		)	2,414		8.1
	Trademarks	6,345		(2,279		)	4,066		8
	In-process R&D acquired	3,600		—			3,600		Indefinite
	Distributor relationships	900		(900		)	—		3
		$	283,782	$	(86,420	)	$	197,362
		31-May-14
		Gross		Accumulated			Net carrying		Weighted
		carrying		amortization			value		avg useful
		value							life
		(in thousands)							(years)
	Product technologies	$	150,298	$	(32,930	)	$	117,368	10.2
	Customer relationships	86,645		(37,848		)	48,797		11.9
	Trademark-NAMIC	28,600		—			28,600		Indefinite
	In process R&D acquired	3,600		—			3,600		Indefinite
	Licenses	7,639		(5,211		)	2,428		8.4
	Trademarks	6,345		(1,882		)	4,463		8
	Distributor relationships	900		(900		)	—		3
		$	284,027	$	(78,771	)	$	205,256

Accrued_Liabilities_Tables

Accrued Liabilities (Tables)	6 Months Ended
	Nov. 30, 2014
Payables and Accruals [Abstract]
Accrued Liabilities	As of November 30, 2014 and May 31, 2014, accrued liabilities consisted of the following:
		Nov 30, 2014		31-May-14
				As revised
		(in thousands)
	Payroll and related expenses	$	8,797	$	8,114
	Royalties	2,343		2,620
	Accrued severance	1,020		765
	Sales and franchise taxes	1,398		1,327
	Interest rate swap liability	400		555
	Other	5,219		3,271
	Total	$	19,177	$	16,652

Income_Taxes_Tables

Income Taxes (Tables)	6 Months Ended
	Nov. 30, 2014
Income Tax Disclosure [Abstract]
Components of Income Tax Expense/(Benefit)	The following table presents the components of income tax expense(benefit) for the three and six months ended November 30, 2014 and 2013 (in thousands of dollars):
		Three Months Ended		Six Months Ended
		Nov 30, 2014	Nov 30, 2013	Nov 30, 2014	Nov 30, 2013
			(As revised)		(As revised)
	Income tax expense (benefit) based on income (loss) from continuing operations at estimated tax rates of 40.9% and 38.8% for the three and six months ended November 30, 2014 and 2013, respectively	$1,140	($150)	$1,738	($354)
	Discrete tax expense (benefit):
	Adjustment for elimination of the ASC 718 APIC pool	330	61	685	61
	Adjustments to prior period tax liabilities	21	—	16	14
	Total income tax expense (benefit)	$1,491	($89)	$2,439	($279)

Earnings_Per_Share_Tables

Earnings Per Share (Tables)	6 Months Ended
	Nov. 30, 2014
Earnings Per Share [Abstract]
Reconciliation of Basic to Diluted Weighted-Average Shares Outstanding	The following table reconciles basic to diluted weighted-average shares outstanding for the three and six months ended November 30, 2014 and 2013 (in thousands):
		Three Months Ended		Six Months Ended
		Nov 30, 2014	Nov 30, 2013	Nov 30, 2014	Nov 30, 2013
	Basic	35,595	35,132	35,475	35,041
	Effect of dilutive securities	532	—	537	—
	Diluted	36,127	35,132	36,012	35,041

Segment_and_Geographic_Informa1

Segment and Geographic Information (Tables)	6 Months Ended
	Nov. 30, 2014
Segment Reporting [Abstract]
Summary of Net Sales by Product Category	The table below summarizes net sales by product category (in thousands of dollars):
		Three Months Ended				Six Months Ended
		Nov 30, 2014		Nov 30, 2013		Nov 30, 2014		Nov 30, 2013
				As revised				As revised
	Net sales
	Peripheral Vascular	$	49,440	$	48,815	$	96,801	$	94,360
	Vascular Access	27,968		25,571		54,393		50,854
	Oncology/Surgery	13,634		12,557		25,996		23,724
	Supply Agreement	1,107		1,628		2,290		3,277
	Total	$	92,149	$	88,571	$	179,480	$	172,215
Summary of Net Sales by Geographic Area	The table below presents net sales by geographic area based on external customer location (in thousands of dollars):
		Three Months Ended				Six Months Ended
		Nov 30, 2014		Nov 30, 2013		Nov 30, 2014		Nov 30, 2013
				As revised				As revised
	Net sales
	United States	$	72,058	$	69,485	$	140,438	$	136,652
	International	18,984		17,458		36,752		32,286
	Supply Agreement	1,107		1,628		2,290		3,277
	Total	$	92,149	$	88,571	$	179,480	$	172,215

Fair_Value_Tables

Fair Value (Tables)	6 Months Ended
	Nov. 30, 2014
Fair Value Disclosures [Abstract]
Fair Value of Assets and Liabilities Measured on a Recurring Basis	The following tables provide information by level for assets and liabilities that are measured at fair value on a recurring basis as of November 30, 2014 and May 31, 2014 (in thousands of dollars):
		Fair Value Measurements using									Fair Value at November 30, 2014
		inputs considered as:
		Level 1				Level 2			Level 3
	Financial Assets
	Cash equivalents
	Money market funds	$	1			$	—		$	—	$	1
	Total	$	1			$	—		$	—	$	1
	Marketable securities
	U.S. government agency obligations	$	—			$	—		$	1,698	$	1,698
	Total	—				—			1,698		1,698
	Total Financial Assets	$	1			$	—		$	1,698	$	1,699
	Financial Liabilities
	Interest rate swap agreements	$	—			$	400		$	—	$	400
	Contingent liability for acquisition earn out	—				—			57,438		57,438
	Total Financial Liabilities	$	—			$	400		$	57,438	$	57,838
		Fair Value Measurements using									Fair Value at May 31, 2014
		inputs considered as:
		Level 1				Level 2			Level 3
	Financial Assets								As revised		As revised
	Cash equivalents
	Money market funds	$	445			$	—		$	—	$	445
	Total	$	445			$	—		$	—	$	445
	Marketable securities
	U.S. government agency obligations	$	—			$	—		$	1,809	$	1,809
	Total	—				—			1,809		1,809
	Total Financial Assets	$	445			$	—		$	1,809	$	2,254
	Financial Liabilities
	Interest rate swap agreements	$	—			$	555		$	—	$	555
	Contingent liability for acquisition earn out	—				—			67,331		67,331
	Total Financial Liabilities	$	—			$	555		$	67,331	$	67,886
Fair Value Measurements Using Significant Unobservable Inputs	The table below presents the components of Level 3 fair value instruments as of November 30, 2014 (in thousands of dollars):
		Financial Assets				Financial Liabilities
		Fair Value Measurements				Fair Value Measurements
		Using Significant				Using Significant
		Unobservable Inputs				Unobservable Inputs
		(Level 3)				(Level 3)
						As revised
	Balance, May 31, 2014	$	1,809			$	67,331
	Earnings revaluation expense - included in earnings	—				1,418
	Currency (gain) loss	—				(89		)
	Included in other comprehensive income	(111		)		—
	Contingent consideration - Microsulis	—				(11,222		)
	Balance, November 30, 2014	$	1,698			$	57,438
Summary Showing the Recurring Fair Value Measurements of the Contingent Consideration Liability	The recurring Level 3 fair value measurements of the contingent consideration liabilities include the following significant unobservable inputs as of November 30, 2014 (in thousands of dollars):
		Fair value at				Valuation
		Nov 30, 2014				Technique		Unobservable Input	Range
	Revenue based payments	$	54,160			Discounted cash flow		Discount rate	4%-10%
								Probability of payment	75-100%
								Projected fiscal year of payment	2016 - 2022
	Milestone based payments	3,278				Discounted cash flow		Discount rate	16%-20%
								Probability of payment	75-100%
								Projected fiscal year of payment	2017
	Total	$	57,438
Summary Showing Reconciliation of the Contingent Payments	The following table provides a reconciliation of the beginning and ending balances of contingent milestone payments measured at fair value that used significant unobservable inputs (Level 3) (in thousands of dollars):
				Total Contingent Consideration
				As revised
	Beginning balance -	31-May-14		$	67,331
	Contingent payments			(11,222		)
	Earnings revaluation expense			1,418
	Currency (gain) loss			(89		)
	Ending balance -	30-Nov-14		$	57,438

Marketable_Securities_Tables

Marketable Securities (Tables)	6 Months Ended
	Nov. 30, 2014
Investments, Debt and Equity Securities [Abstract]
Marketable Securities	As of November 30, 2014 and May 31, 2014, marketable securities consisted of the following (in thousands of dollars):
	As of November 30, 2014	Amortized		Gross		Gross			Fair Value
		cost		Unrealized		Unrealized
				Gains		Losses
	Available-for-sales securities
	U.S. government agency obligations	$	1,825	$	—	$	(127	)	$	1,698
		$	1,825	$	—	$	(127	)	$	1,698
	As of May 31, 2014	Amortized		Gross		Gross			Fair Value
		cost		Unrealized		Unrealized
				Gains		Losses
	Available-for-sales securities
	U.S. government agency obligations	$	1,825	$	—	$	(16	)	$	1,809
		$	1,825	$	—	$	(16	)	$	1,809

Immaterial_Corrections_Tables

Immaterial Corrections (Tables)	6 Months Ended
	Nov. 30, 2014
Accounting Changes and Error Corrections [Abstract]
Schedule of Error Corrections and Prior Period Adjustments	The impacts of these revisions are shown in the tables below:
		Three months ended August 31, 2013
		As previously reported			Adjustments			As revised
	Net sales	$	83,579		$	65		$	83,644
	Cost of sales	41,097			(33		)	41,064
	Gross profit	42,482			98			42,580
	Total operating expenses	41,195			(17		)	41,178
	Operating income	1,287			115			1,402
	Total other income (expenses)	(1,934		)	(31		)	(1,965		)
	Income (loss) before taxes	(647		)	84			(563		)
	Income tax benefit (expense)	221			(31		)	190
	Net income (loss)	(426		)	53			(373		)
	Total comprehensive income (loss), net of tax	(155		)	53			(102		)
		Three months ended November 30, 2013
		As previously reported			Adjustments			As revised
	Net sales	$	88,616		$	(45	)	$	88,571
	Cost of sales	43,686			—			43,686
	Gross profit	44,930			(45		)	44,885
	Total operating expenses	43,356			88			43,444
	Operating income	1,574			(133		)	1,441
	Total other income (expense)	(1,660		)	(131		)	(1,791		)
	Income (loss) before taxes	(86		)	(264		)	(350		)
	Income tax benefit (expense)	(13		)	102			89
	Net income (loss)	(99		)	(162		)	(261		)
	Total comprehensive income (loss), net of tax	(358		)	(162		)	(520		)
		Six months ended November 30, 2013
		As previously reported			Adjustments			As revised
	Net sales	$	172,195		$	20		$	172,215
	Cost of sales	84,783			(33		)	84,750
	Gross profit	87,412			53			87,465
	Total operating expenses	84,551			71			84,622
	Operating income	2,861			(18		)	2,843
	Total other income (expense)	(3,594		)	(162		)	(3,756		)
	Income (loss) before taxes	(733		)	(180		)	(913		)
	Income tax benefit (expense)	208			71			279
	Net income (loss)	(525		)	(109		)	(634		)
	Total comprehensive income (loss), net of tax	(513		)	(109		)	(622		)
		Three months ended February 28, 2014
		As previously reported			Adjustments			As revised
	Net sales	$	88,195		$	(45	)	$	88,150
	Cost of sales	43,277			80			43,357
	Gross profit	44,918			(125		)	44,793
	Total operating expenses	38,066			214			38,280
	Operating income	6,852			(339		)	6,513
	Total other income (expense)	(1,985		)	15			(1,970		)
	Income (loss) before taxes	4,867			(324		)	4,543
	Income tax benefit (expense)	(176		)	148			(28		)
	Net income (loss)	4,691			(176		)	4,515
	Total comprehensive income (loss), net of tax	4,869			(176		)	4,693
		Nine months ended February 28, 2014
		As previously reported			Adjustments			As revised
	Net sales	$	260,390		$	(25	)	$	260,365
	Cost of sales	128,060			47			128,107
	Gross profit	132,330			(72		)	132,258
	Total operating expenses	122,617			285			122,902
	Operating income	9,713			(357		)	9,356
	Total other income (expense)	(5,579		)	(147		)	(5,726		)
	Income (loss) before taxes	4,134			(504		)	3,630
	Income tax benefit (expense)	32			219			251
	Net income (loss)	4,166			(285		)	3,881
	Total comprehensive income (loss), net of tax	4,356			(285		)	4,071
		Three months ended May 31, 2014
		As previously reported			Adjustments			As revised
	Net sales	$	94,065		$	(5	)	$	94,060
Cost of sales	46,534			116			46,650
Gross profit	47,531			(121		)	47,410
Total operating expenses	43,796			30			43,826
Operating income	3,735			(151		)	3,584
Total other income (expense)	(1,489		)	15			(1,474		)
Income (loss) before taxes	2,246			(136		)	2,110
Income tax benefit (expense)	(3,324		)	(1		)	(3,325		)
Net income (loss)	(1,078		)	(137		)	(1,215		)
Total comprehensive income (loss), net of tax	(1,003		)	(137		)	(1,140		)
	Year ended May 31, 2014
	As previously reported			Adjustments			As revised
Net sales	$	354,455		$	(30	)	$	354,425
Cost of sales	174,594			163			174,757
Gross profit	179,861			(193		)	179,668
Total operating expenses	166,413			315			166,728
Operating income	13,448			(508		)	12,940
Total other income (expense)	(7,068		)	(132		)	(7,200		)
Income (loss) before taxes	6,380			(640		)	5,740
Income tax benefit (expense)	(3,292		)	218			(3,074		)
Net income (loss)	3,088			(422		)	2,666
Total comprehensive income (loss), net of tax	3.353			(422		)	2.931
	Year ended May 31, 2014
	As previously reported			Adjustments			As revised
Net cash provided by (used in) operating activities	$	25,280		$	(599	)	$	24,681
Net cash provided by (used in) investing activities	(17,047		)	599			(16,448		)
Net cash provided by (used in) financing activities	(14,016		)	—			(14,016		)
	As of May 31, 2014
	As previously reported			Adjustments			As revised
Accounts receivable, net of allowances	$	62,148		$	(180	)	$	61,968
Inventories	61,056			178			61,234
Prepaid expenses and other	5,975			(504		)	5,471
Total current assets	152,228			(506		)	151,722
Property, plant and equipment, net	67,208			(618		)	66,590
Other assets	4,876			(950		)	3,926
Goodwill	360,294			179			360,473
Deferred income taxes, long term	9,767			636			10,403
Total assets	800,150			(1,259		)	798,891
Accrued liabilities	16,762			(110		)	16,652
Current portion of contingent payments	16,341			(5,423		)	10,918
Total current liabilities	72,286			(5,533		)	66,753
Contingent consideration, net of current portion	51,080			5,333			56,413
Total liabilities	262,256			(200		)	262,056
Additional paid-in capital	508,263			91			508,354
Retained earnings	32,651			(1,150		)	31,501
Total stockholders' equity	537,894			(1,059		)	536,835
	Year ended May 31, 2013
	As previously reported			Adjustments			As revised
Net sales	$	342,026		$	(110	)	$	341,916
Cost of sales	173,037			365			173,402
Gross profit	168,989			(475		)	168,514
Total operating expenses	161,895			331			162,226
Operating income	7,094			(806		)	6,288
Total other income (expense)	(7,737		)	(138		)	(7,875		)
Income (loss) before taxes	(643		)	(944		)	(1,587		)
Income tax benefit (expense)	31			345			376
Net income (loss)	(612		)	(599		)	(1,211		)
Total comprehensive income (loss), net of tax	(872		)	(599		)	(1,471		)
	Year ended May 31, 2013
	As previously reported			Adjustments			As revised
Net cash provided by (used in) operating activities	$	26,883		$	(231	)	$	26,652
Net cash provided by (used in) investing activities	(22,238		)	—			(22,238		)
Net cash provided by (used in) financing activities	(6,286		)	—			(6,286		)
	As of May 31, 2013
	As previously reported			Adjustments			As revised
Accounts receivable, net of allowances	$	47,791		$	(110	)	$	47,681
Inventories	55,062			17			55,079
Prepaid expenses and other	7,554			(269		)	7,285
Total current assets	141,516			(362		)	141,154
Property, plant and equipment, net	62,650			(259		)	62,391
Other assets	5,559			(651		)	4,908
Intangible assets, net	214,848			(175		)	214,673
Goodwill	355,458			179			355,637
Deferred income taxes, long term	11,007			418			11,425
Total assets	791,584			(850		)	790,734
Accounts payable	24,522			(52		)	24,470
Accrued liabilities	16,426			(70		)	16,356
Total current liabilities	63,437			(122		)	63,315
Total liabilities	264,754			(122		)	264,632
Retained earnings	29,563			(728		)	28,835
Total stockholders' equity	526,830			(728		)	526,102
	Year ended May 31, 2012
	As previously reported			Adjustments			As revised
Net sales	$	221,787		$	130		$	221,917
Cost of sales	95,829			779			96,608
Gross profit	125,958			(649		)	125,309
Total operating expenses	128,920			297			129,217
Operating income	(2,962		)	(946		)	(3,908		)
Total other income (expense)	(2,320		)	806			(1,514		)
Income (loss) before taxes	(5,282		)	(140		)	(5,422		)
Income tax expense (benefit)	188			51			239
Net income (loss)	(5,094		)	(89		)	(5,183		)
Total comprehensive income (loss), net of tax	(5,095		)	(89		)	(5,184		)
	Year ended May 31, 2012
	As previously reported			Adjustments			As revised
Net cash provided by (used in) operating activities	$	11,497		$	105		$	11,602
Net cash provided by (used in) investing activities	(176,360		)	126			(176,234		)
Net cash provided by (used in) financing activities	142,338			—			142,338
	As of May 31, 2012
	As previously reported			Adjustments			As revised
Cash and cash equivalents	$	23,508		$	231		$	23,739
Accounts receivable, net of allowances	48,588			(1,685		)	46,903
Prepaid expenses and other	9,826			(23		)	9,803
Total current assets	159,238			(1,477		)	157,761
Property, plant and equipment, net	55,915			(305		)	55,610
Other assets	10,707			(348		)	10,359
Intangible assets, net	147,266			97			147,363
Goodwill	308,912			179			309,091
Deferred income taxes, long term	39,198			73			39,271
Total assets	721,769			(1,781		)	719,988
Accrued liabilities	18,722			(1,652		)	17,070
Total current liabilities	55,422			(1,652		)	53,770
Total liabilities	198,249			(1,652		)	196,597
Retained earnings	30,175			(129		)	30,046
Total stockholders' equity	523,520			(129		)	523,391

Consolidated_Financial_Stateme1

Consolidated Financial Statements - Additional Information (Detail) (USD $)	0 Months Ended
In Millions, unless otherwise specified	Sep. 19, 2013	Sep. 19, 2013
Recent Developments [Line Items]
Ratio for debt service coverage	1.35
Ratio of indebtedness to consolidated EBITDA	3.75	3.75
New Credit Agreement [Member]
Recent Developments [Line Items]
Percentage of increase in interest	2.00%
New Credit Agreement [Member] | Term Loan Facility [Member]
Recent Developments [Line Items]
Senior secured term loan facility	100	100
Term loan quarterly repayment, year one	5.00%
Term loan quarterly repayment, year two	5.00%
Term loan quarterly repayment, year three	10.00%
Term loan quarterly repayment, year four	15.00%
Term loan quarterly repayment, year five	65.00%
New Credit Agreement [Member] | Senior Secured Revolving Credit Facility [Member]
Recent Developments [Line Items]
Senior secured term loan facility	100	100
New Credit Agreement [Member] | Senior Secured Revolving Credit Facility [Member] | Minimum [Member]
Recent Developments [Line Items]
Commitment fee, percentage	0.20%
New Credit Agreement [Member] | Senior Secured Revolving Credit Facility [Member] | Maximum [Member]
Recent Developments [Line Items]
Commitment fee, percentage	0.35%
New Credit Agreement [Member] | Letters of Credit [Member]
Recent Developments [Line Items]
Senior secured term loan facility	20	20
New Credit Agreement [Member] | Swingline Loans [Member]
Recent Developments [Line Items]
Senior secured term loan facility	5	5
New Credit Agreement [Member] | Revolving Credit Facility [Member]
Recent Developments [Line Items]
Initial amount borrowed under revolving facility	41.4	41.4
New Credit Agreement [Member] | Base Rate [Member] | JP Morgan Chase [Member]
Recent Developments [Line Items]
Percentage of increases leverage ratio base rate, minimum	0.50%
Percentage of increases leverage ratio base rate, maximum	1.25%
New Credit Agreement [Member] | Eurodollar [Member] | JP Morgan Chase [Member]
Recent Developments [Line Items]
Percentage of increases leverage ratio base rate, minimum	1.50%
Percentage of increases leverage ratio base rate, maximum	2.25%

Acquisitions_Additional_Inform

Acquisitions - Additional Information (Detail) (USD $)	6 Months Ended		12 Months Ended	1 Months Ended
	Nov. 30, 2014	Nov. 30, 2013	31-May-13	Aug. 15, 2013	31-May-14	31-May-12
Business Acquisition [Line Items]
Goodwill acquired	$360,473,000		$355,637,000		$360,473,000	$309,091,000
Estimated useful life			3 years
Upfront payment included in total estimated purchase consideration	250,000	150,000
Minimum [Member]
Business Acquisition [Line Items]
Estimated useful life	3 years
Maximum [Member]
Business Acquisition [Line Items]
Estimated useful life	15 years
Clinical Devices B.V [Member]
Business Acquisition [Line Items]
Cash payments at closing total				3,700,000
Business acquisition purchase price holdback amount				400,000
Total purchase				8,700,000
Present value of contingent consideration liability				5,000,000
Goodwill acquired				4,800,000
Intangible assets other than goodwill				5,100,000
Deferred tax liability				1,200,000
In Process Research and Development [Member] | Clinical Devices, B.V. [Member]
Business Acquisition [Line Items]
Intangible assets other than goodwill				3,600,000
Customer Relationships [Member]
Business Acquisition [Line Items]
Estimated useful life	12 years		11 years 10 months 24 days
Customer Relationships [Member] | Clinical Devices B.V [Member]
Business Acquisition [Line Items]
Estimated useful life				15 years
Customer Relationships [Member] | Clinical Devices, B.V. [Member]
Business Acquisition [Line Items]
Finite-Lived Customer Relationships, Gross				1,400,000
Trademarks [Member]
Business Acquisition [Line Items]
Estimated useful life	8 years		8 years
Trademarks [Member] | Clinical Devices B.V [Member]
Business Acquisition [Line Items]
Estimated useful life				5 years
Trademarks [Member] | Clinical Devices, B.V. [Member]
Business Acquisition [Line Items]
Acquired finite lived intangible assets				70,000

Inventories_Schedule_of_Invent

Inventories - Schedule of Inventories (Detail) (USD $)	Nov. 30, 2014	31-May-14	31-May-13
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]
Raw materials	$30,000	$24,734
Work in process	11,774	11,992
Finished goods	33,541	24,508
Inventories	$75,315	$61,234	$55,079

Goodwill_and_Intangible_Assets2

Goodwill and Intangible Assets - Additional Information (Detail)	12 Months Ended	6 Months Ended
	31-May-13	Nov. 30, 2014
Finite-Lived Intangible Assets [Line Items]
Estimated useful life of intangible assets other than goodwill	3 years
Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful life of intangible assets other than goodwill		15 years
Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful life of intangible assets other than goodwill		3 years

Goodwill_and_Intangible_Assets3

Goodwill and Intangible Assets - Goodwill by Segment (Detail) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Nov. 30, 2014	31-May-14	31-May-13	31-May-12	Aug. 15, 2013
Goodwill [Line Items]
Goodwill, Beginning Balance		$360,473	$355,637	$309,091
Goodwill, Ending Balance	360,473	360,473	355,637	309,091
Clinical Devices B.V [Member]
Goodwill [Line Items]
Goodwill, Beginning Balance					4,800
Acquisition	0
Goodwill, Ending Balance					$4,800

Goodwill_and_Intangible_Assets4

Goodwill and Intangible Assets - Intangible Assets (Detail) (USD $)	12 Months Ended	6 Months Ended
In Thousands, unless otherwise specified	31-May-13	Nov. 30, 2014	31-May-14	31-May-12
Finite-Lived Intangible Assets [Line Items]
Gross carrying value, excluding goodwill		$283,782	$284,027
Accumulated amortization		-86,420	-78,771
Net carrying value, excluding goodwill	214,673	197,362	205,256	147,363
Weighted avg useful life	3 years
Product Technologies [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying value, finite intangible items		150,288	150,298
Accumulated amortization		-37,430	-32,930
Net carrying value, finite intangible items		112,858	117,368
Weighted avg useful life	10 years 2 months 12 days	10 years 3 months 18 days
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying value, finite intangible items		86,347	86,645
Accumulated amortization		-40,523	-37,848
Net carrying value, finite intangible items		45,824	48,797
Weighted avg useful life	11 years 10 months 24 days	12 years
Licenses [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying value, finite intangible items		7,702	7,639
Accumulated amortization		-5,288	-5,211
Net carrying value, finite intangible items		2,414	2,428
Weighted avg useful life	8 years 4 months 24 days	8 years 1 month 3 days
Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying value, finite intangible items		6,345	6,345
Accumulated amortization		-2,279	-1,882
Net carrying value, finite intangible items		4,066	4,463
Weighted avg useful life	8 years	8 years
Distributor Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying value, finite intangible items		900	900
Accumulated amortization		-900	-900
Net carrying value, finite intangible items		0	0
Weighted avg useful life		3 years
Trademark-NAMIC [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying value, indefinite items		28,600	28,600
Accumulated amortization		0	0
Net carrying value, indefinite items		28,600	28,600
In-process Research and Development [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying value, indefinite items		3,600	3,600
Accumulated amortization		0	0
Net carrying value, indefinite items		$3,600	$3,600

Accrued_Liabilities_Summary_of

Accrued Liabilities - Summary of Accrued Liabilities (Detail) (USD $)	Nov. 30, 2014	31-May-14	31-May-13	31-May-12
In Thousands, unless otherwise specified
Other Liabilities Disclosure [Abstract]
Payroll and related expenses	$8,797	$8,114
Royalties	2,343	2,620
Accrued severance	1,020	765
Sales and franchise taxes	1,398	1,327
Interest rate swap liability	400	555
Other	5,219	3,271
Total	$19,177	$16,652	$16,356	$17,070

Long_Term_Debt_Additional_Info

Long Term Debt - Additional Information (Detail) (USD $)	0 Months Ended
	Sep. 19, 2013	Nov. 30, 2014	31-May-14	Sep. 19, 2013
Debt Instrument [Line Items]
Notional amount of interest rate swap agreement	$100,000,000			$100,000,000
Fixed interest rate payments	0.74%			0.74%
LONG-TERM DEBT, term loan, net of current portion		87,500,000	91,250,000
Ratio for debt service coverage	1.35
Ratio of indebtedness to consolidated EBITDA	3.75			3.75
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
LONG-TERM DEBT, term loan, net of current portion	61,400,000			61,400,000
New Credit Agreement [Member]
Debt Instrument [Line Items]
Percentage of increase in interest	2.00%
New Credit Agreement [Member] | Base Rate [Member] | JP Morgan Chase [Member]
Debt Instrument [Line Items]
Percentage of increases leverage ratio base rate, minimum	0.50%
Percentage of increases leverage ratio base rate, maximum	1.25%
New Credit Agreement [Member] | Eurodollar [Member] | JP Morgan Chase [Member]
Debt Instrument [Line Items]
Percentage of increases leverage ratio base rate, minimum	1.50%
Percentage of increases leverage ratio base rate, maximum	2.25%
New Credit Agreement [Member] | Term Loan Facility [Member]
Debt Instrument [Line Items]
Senior secured term loan facility	100,000,000			100,000,000
Term loan quarterly repayment, year one	5.00%
Term loan quarterly repayment, year two	5.00%
Term loan quarterly repayment, year three	10.00%
Term loan quarterly repayment, year four	15.00%
Term loan quarterly repayment, year five	65.00%
New Credit Agreement [Member] | Senior Secured Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Senior secured term loan facility	100,000,000			100,000,000
New Credit Agreement [Member] | Senior Secured Revolving Credit Facility [Member] | Minimum [Member]
Debt Instrument [Line Items]
Commitment fee percentage	0.20%
New Credit Agreement [Member] | Senior Secured Revolving Credit Facility [Member] | Maximum [Member]
Debt Instrument [Line Items]
Commitment fee percentage	0.35%
New Credit Agreement [Member] | Letters of Credit [Member]
Debt Instrument [Line Items]
Senior secured term loan facility	20,000,000			20,000,000
New Credit Agreement [Member] | Swingline Loans [Member]
Debt Instrument [Line Items]
Senior secured term loan facility	5,000,000			5,000,000
New Credit Agreement [Member] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Initial amount borrowed under revolving facility	41,400,000			41,400,000
Term Loan [Member]
Debt Instrument [Line Items]
LONG-TERM DEBT, term loan, net of current portion	$93,800,000			$93,800,000

Income_Taxes_Components_of_Inc

Income Taxes - Components of Income Tax Expense/(Benefit) (Detail) (USD $)	3 Months Ended					6 Months Ended		9 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Nov. 30, 2014	31-May-14	Feb. 28, 2014	Nov. 30, 2013	Aug. 31, 2012	Nov. 30, 2014	Nov. 30, 2013	Feb. 28, 2014	31-May-14	31-May-13	31-May-12
Income Tax Disclosure [Abstract]
Income tax expense (benefit) based on income (loss) from continuing operations at estimated tax rates of 42.2% in 2014 and 37.4% in 2013	$1,140			($150)		$1,738	($354)
Discrete tax expense/(benefit):
Adjustment for elimination of the ASC 718 APIC pool	330			61		685	61
Adjustments to prior period tax liabilities	21			0		16	14
Total income tax expense (benefit)	$1,491	$3,325	$28	($89)	($190)	$2,439	($279)	($251)	$3,074	($376)	($239)

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Nov. 30, 2014	Nov. 30, 2013	Nov. 30, 2014
Income Tax Disclosure [Abstract]
Effective income tax rate	40.90%	38.80%
Taxable income per year for the next nine years			$10
Taxable income per year for the final eight years			$6.50

ShareBased_Compensation_Detail

Share-Based Compensation (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Nov. 30, 2014	Nov. 30, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Amount of shares issuable through two stock-based compensation plans	5.8
Charges against income for share-based payment arrangements	$1.50	$1.30
Unrecognized compensation expenses related to share-based payment arrangements	$13.30

Earnings_Per_Share_Reconciliat

Earnings Per Share - Reconciliation of Basic to Diluted Weighted-Average Shares Outstanding (Detail)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Nov. 30, 2014	Nov. 30, 2013	Nov. 30, 2014	Nov. 30, 2013
Earnings Per Share [Abstract]
Basic	35,595	35,132	35,475	35,041
Effect of dilutive securities	532	0	537	0
Diluted	36,127	35,132	36,012	35,041

Earnings_Per_Share_Additional_

Earnings Per Share - Additional Information (Detail)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Nov. 30, 2014	Nov. 30, 2013	Nov. 30, 2014	Nov. 30, 2013
Earnings Per Share [Abstract]
Securities excluded from computation of diluted earnings per share	0.8	2.3	0.9	2.7

Segment_and_Geographic_Informa2

Segment and Geographic Information - Additional Information (Detail)	6 Months Ended
	Nov. 30, 2013
	Segment
Segment Reporting [Abstract]
Number of segment	1

Segment_and_Geographic_Informa3

Segment and Geographic Information - Summary of Net Sales by Product Category (Detail) (USD $)	3 Months Ended					6 Months Ended		9 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Nov. 30, 2014	31-May-14	Feb. 28, 2014	Nov. 30, 2013	Aug. 31, 2012	Nov. 30, 2014	Nov. 30, 2013	Feb. 28, 2014	31-May-14	31-May-13	31-May-12
Segment Reporting Information [Line Items]
Net sales	$92,149	$94,060	$88,150	$88,571	$83,644	$179,480	$172,215	$260,365	$354,425	$341,916	$221,917
Peripheral Vascular [Member]
Segment Reporting Information [Line Items]
Net sales	49,440			48,815		96,801	94,360
Vascular Access [Member]
Segment Reporting Information [Line Items]
Net sales	27,968			25,571		54,393	50,854
Oncology/Surgery [Member]
Segment Reporting Information [Line Items]
Net sales	13,634			12,557		25,996	23,724
Supply Agreement [Member]
Segment Reporting Information [Line Items]
Net sales	$1,107			$1,628		$2,290	$3,277

Segment_and_Geographic_Informa4

Segment and Geographic Information - Summary of Net Sales by Geographic Area (Detail) (USD $)	3 Months Ended					6 Months Ended		9 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Nov. 30, 2014	31-May-14	Feb. 28, 2014	Nov. 30, 2013	Aug. 31, 2012	Nov. 30, 2014	Nov. 30, 2013	Feb. 28, 2014	31-May-14	31-May-13	31-May-12
Net Sales
Net sales	$92,149	$94,060	$88,150	$88,571	$83,644	$179,480	$172,215	$260,365	$354,425	$341,916	$221,917
Supply Agreement [Member]
Net Sales
Net sales	1,107			1,628		2,290	3,277
Reportable Geographical Components [Member] | United States [Member]
Net Sales
Net sales	72,058			69,485		140,438	136,652
Reportable Geographical Components [Member] | International [Member]
Net Sales
Net sales	18,984			17,458		36,752	32,286
Reportable Geographical Components [Member] | Supply Agreement [Member]
Net Sales
Net sales	$1,107			$1,628		$2,290	$3,277

Fair_Value_Additional_Informat

Fair Value - Additional Information (Detail) (USD $)	Nov. 30, 2014
In Millions, unless otherwise specified
Fair Value Disclosures [Abstract]
Potential amount of undiscounted future contingent consideration	$67.70
Fair value of contingent milestone payments, current portion	47.6
Fair value of contingent milestone payments, long term portion	$9.80

Fair_Value_Fair_Value_of_Asset

Fair Value - Fair Value of Assets and Liabilities Measured on a Recurring Basis (Detail) (USD $)	Nov. 30, 2014	31-May-14
In Thousands, unless otherwise specified
Recurring [Member]
Financial Assets
Cash equivalents	$1	$445
Marketable securities	1,698	1,809
Total Financial Assets	1,699	2,254
Financial Liabilities
Total Financial Liabilities	57,838	67,886
Recurring [Member] | Money Market Funds [Member]
Financial Assets
Cash equivalents	1	445
Recurring [Member] | U.S. Government Agency Obligations [Member]
Financial Assets
Marketable securities	1,698	1,809
Interest Rate Swap Agreements [Member] | Recurring [Member]
Financial Liabilities
Total Financial Liabilities	400	555
Contingent Consideration Earn Out Liability [Member]
Financial Liabilities
Total Financial Liabilities	57,438
Contingent Consideration Earn Out Liability [Member] | Recurring [Member]
Financial Liabilities
Total Financial Liabilities		67,331
Level 1 [Member] | Recurring [Member]
Financial Assets
Cash equivalents	1	445
Marketable securities	0	0
Total Financial Assets	1	445
Financial Liabilities
Total Financial Liabilities	0	0
Level 1 [Member] | Recurring [Member] | Money Market Funds [Member]
Financial Assets
Cash equivalents	1	445
Level 1 [Member] | Recurring [Member] | U.S. Government Agency Obligations [Member]
Financial Assets
Marketable securities	0	0
Level 1 [Member] | Interest Rate Swap Agreements [Member] | Recurring [Member]
Financial Liabilities
Total Financial Liabilities	0	0
Level 1 [Member] | Contingent Consideration Earn Out Liability [Member] | Recurring [Member]
Financial Liabilities
Total Financial Liabilities	0
Level 2 [Member] | Recurring [Member]
Financial Assets
Cash equivalents	0	0
Marketable securities	0	0
Total Financial Assets	0	0
Financial Liabilities
Total Financial Liabilities	400	555
Level 2 [Member] | Recurring [Member] | Money Market Funds [Member]
Financial Assets
Cash equivalents	0	0
Level 2 [Member] | Recurring [Member] | U.S. Government Agency Obligations [Member]
Financial Assets
Marketable securities	0	0
Level 2 [Member] | Interest Rate Swap Agreements [Member] | Recurring [Member]
Financial Liabilities
Total Financial Liabilities	400	555
Level 2 [Member] | Contingent Consideration Earn Out Liability [Member] | Recurring [Member]
Financial Liabilities
Total Financial Liabilities	0
Level 3 [Member] | Recurring [Member]
Financial Assets
Cash equivalents	0	0
Marketable securities	1,698	1,809
Total Financial Assets	1,698	1,809
Financial Liabilities
Total Financial Liabilities	57,438	67,331
Level 3 [Member] | Recurring [Member] | Money Market Funds [Member]
Financial Assets
Cash equivalents	0	0
Level 3 [Member] | Recurring [Member] | U.S. Government Agency Obligations [Member]
Financial Assets
Marketable securities	1,698	1,809
Level 3 [Member] | Interest Rate Swap Agreements [Member] | Recurring [Member]
Financial Liabilities
Total Financial Liabilities	0	0
Level 3 [Member] | Contingent Consideration Earn Out Liability [Member] | Recurring [Member]
Financial Liabilities
Total Financial Liabilities	$57,438	$67,331

Fair_Value_Fair_Value_Measurem

Fair Value - Fair Value Measurements Using Significant Unobservable Inputs (Detail) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Nov. 30, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets, begining balance	$1,809
Financial liabilities, begining balance	67,331
Earnings revaluation expense - included in earnings, assets	0
Earnings revaluation expense - included in earnings, liabilities	1,418
Currency translation adjustment, assets	0
Currency translation adjustment, liabilities	-89
Included in other comprehensive income, assets	111
Included in other comprehensive income, liabilities	0
Contingent consideration - Clinical Devices, assets	0
Financial assets, ending balance	1,698
Financial liabilities, ending balance	57,438
Clinical Devices B.V [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration - Clinical Devices, liabilities	($11,222)

Fair_Value_Summary_Showing_the

Fair Value - Summary Showing the Recurring Fair Value Measurements of the Contingent Consideration Liability (Detail) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Nov. 30, 2014	31-May-14
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
30-Nov-14	57,438	$67,331
Contingent Consideration Earn Out Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total fair value financial liabilities	57,438
Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total fair value financial liabilities	57,838	67,886
Recurring [Member] | Contingent Consideration Earn Out Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total fair value financial liabilities		67,331
Level 3 [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total fair value financial liabilities	57,438	67,331
Level 3 [Member] | Recurring [Member] | Contingent Consideration Earn Out Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total fair value financial liabilities	57,438	67,331
Level 3 [Member] | Revenue Based Payments [Member] | Recurring [Member] | Contingent Consideration Earn Out Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
30-Nov-14	54,160
Level 3 [Member] | Revenue Based Payments [Member] | Minimum [Member] | Recurring [Member] | Contingent Consideration Earn Out Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Discount rate	4.00%
Probability of payment	75.00%
Projected fiscal year of payment	2015
Level 3 [Member] | Revenue Based Payments [Member] | Maximum [Member] | Recurring [Member] | Contingent Consideration Earn Out Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Discount rate	10.00%
Probability of payment	100.00%
Projected fiscal year of payment	2022
Level 3 [Member] | Milestone Based Payments [Member] | Recurring [Member] | Contingent Consideration Earn Out Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
30-Nov-14	3,278
Level 3 [Member] | Milestone Based Payments [Member] | Minimum [Member] | Recurring [Member] | Contingent Consideration Earn Out Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Discount rate	16.00%
Probability of payment	75.00%
Projected fiscal year of payment	2015
Level 3 [Member] | Milestone Based Payments [Member] | Maximum [Member] | Recurring [Member] | Contingent Consideration Earn Out Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Discount rate	20.00%
Probability of payment	100.00%
Projected fiscal year of payment	2017

Fair_Value_Summary_Showing_Rec

Fair Value - Summary Showing Reconciliation of the Contingent Payments (Detail) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Nov. 30, 2014	31-May-14
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Earnings revaluation expense	$1,418
Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Currency Translation Adjustment	-89
30-Nov-14	57,438	67,331
Contingent Consideration Earn Out Liability [Member] | Vortex, Microsulis and Clinical Devices [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
31-May-14	67,331
Contingent payments	-11,222
Earnings revaluation expense	$1,418

Marketable_Securities_Addition

Marketable Securities - Additional Information (Detail) (USD $)	Nov. 30, 2014	31-May-14
In Millions, unless otherwise specified	Investment
Marketable Securities [Abstract]
Investments in auction rate securities that failed auctions	$1.70	$1.80
Number of investments	2

Marketable_Securities_Marketab

Marketable Securities - Marketable Securities (Detail) (USD $)	Nov. 30, 2014	31-May-14
In Thousands, unless otherwise specified
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	$1,825	$1,825
Gross Unrealized Gains	0	0
Gross Unrealized Losses	-127	-16
Fair Value	1,698	1,809
U.S. Government Agency Obligations [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	1,825	1,825
Gross Unrealized Gains	0	0
Gross Unrealized Losses	-127	-16
Fair Value	$1,698	$1,809

Commitments_and_Continfencies_

Commitments and Continfencies - Additional Information (Detail) (USD $)	0 Months Ended			6 Months Ended
In Millions, unless otherwise specified	Mar. 18, 2014	Nov. 08, 2012	Jan. 02, 2008	Nov. 30, 2014
			Lawsuit	patent_claim
				Petition
Loss Contingencies [Line Items]
Litigation settlement amount	$74.90
Biolitec [Member]
Loss Contingencies [Line Items]
Number of lawsuits against biolitec previously settled for which seeking defense and indemnification			2
Partial judgment granted		$23.20
C.R. Bard, Inc. [Member]
Loss Contingencies [Line Items]
Number of petitions filed for reexamination of patents				3
Patent claims				41,000
Rejected patent claims				40,000

Restructuring_Additional_Infor

Restructuring - Additional Information (Detail) (USD $)	3 Months Ended	6 Months Ended
In Millions, unless otherwise specified	Nov. 30, 2014	Nov. 30, 2014
Restructuring Cost and Reserve [Line Items]
Severance expense	$0.10	$1.10

Immaterial_Corrections_Details

Immaterial Corrections (Details) (USD $)	3 Months Ended					6 Months Ended		9 Months Ended	12 Months Ended
	Nov. 30, 2014	31-May-14	Feb. 28, 2014	Nov. 30, 2013	Aug. 31, 2012	Nov. 30, 2014	Nov. 30, 2013	Feb. 28, 2014	31-May-14	31-May-13	31-May-12	Aug. 31, 2013
Net sales	$92,149,000	$94,060,000	$88,150,000	$88,571,000	$83,644,000	$179,480,000	$172,215,000	$260,365,000	$354,425,000	$341,916,000	$221,917,000
Cost of sales	44,493,000	46,650,000	43,357,000	43,686,000	41,064,000	85,999,000	84,750,000	128,107,000	174,757,000	173,402,000	96,608,000
Gross profit	47,656,000	47,410,000	44,793,000	44,885,000	42,580,000	93,481,000	87,465,000	132,258,000	179,668,000	168,514,000	125,309,000
Total operating expenses	43,081,000	43,826,000	38,280,000	43,444,000	41,178,000	85,664,000	84,622,000	122,902,000	166,728,000	162,226,000	129,217,000
Operating income	4,575,000	3,584,000	6,513,000	1,441,000	1,402,000	7,817,000	2,843,000	9,356,000	12,940,000	6,288,000	-3,908,000
Total other income (expenses)	-1,746,000	-1,474,000	-1,970,000	-1,791,000	-1,965,000	-3,570,000	-3,756,000	-5,726,000	-7,200,000	-7,875,000	-1,514,000
Income (loss) before taxes	2,829,000	2,110,000	4,543,000	-350,000	-563,000	4,247,000	-913,000	3,630,000	5,740,000	-1,587,000	-5,422,000
Income tax expense (benefit)	-1,491,000	-3,325,000	-28,000	89,000	190,000	-2,439,000	279,000	251,000	-3,074,000	376,000	239,000
Net income (loss)	1,338,000	-1,215,000	4,515,000	-261,000	-373,000	1,808,000	-634,000	3,881,000	2,666,000	-1,211,000	-5,183,000
Net cash provided by (used in) operating activities									24,681,000	26,652,000	11,602,000
Net cash provided by (used in) investing activities									-16,448,000	-22,238,000	-176,234,000
Net cash provided by (used in) financing activities									-14,016,000	-6,286,000	142,338,000
Cash and cash equivalents	14,877,000	16,105,000				14,877,000			16,105,000	21,802,000	23,739,000	15,173,000
Accounts receivable, net of allowances	58,556,000	61,968,000				58,556,000			61,968,000	47,681,000	46,903,000
Inventories	75,315,000	61,234,000				75,315,000			61,234,000	55,079,000
Prepaid expenses and other	6,753,000	5,471,000				6,753,000			5,471,000	7,285,000	9,803,000
Total current assets	163,446,000	151,722,000				163,446,000			151,722,000	141,154,000	157,761,000
PROPERTY, PLANT AND EQUIPMENT-AT COST, net	67,552,000	66,590,000				67,552,000			66,590,000	62,391,000	55,610,000
OTHER ASSETS	2,741,000	3,926,000				2,741,000			3,926,000	4,908,000	10,359,000
GOODWILL	360,473,000	360,473,000				360,473,000			360,473,000	355,637,000	309,091,000
DEFERRED INCOME TAXES, long term	7,236,000	10,403,000				7,236,000			10,403,000	11,425,000	39,271,000
Total assets	799,331,000	798,891,000				799,331,000			798,891,000	790,734,000	719,988,000
Accrued liabilities	19,177,000	16,652,000				19,177,000			16,652,000	16,356,000	17,070,000
Current portion of contingent payments		10,918,000							10,918,000
Total current liabilities	57,937,000	66,753,000				57,937,000			66,753,000	63,315,000	53,770,000
Contingent consideration, net of current portion		56,413,000							56,413,000
Total liabilities	255,760,000	262,056,000				255,760,000			262,056,000	264,632,000	196,597,000
Additional paid-in capital	513,353,000	508,354,000				513,353,000			508,354,000
Retained earnings	33,309,000	31,501,000				33,309,000			31,501,000	28,835,000	30,046,000
Total stockholders' equity	543,571,000	536,835,000				543,571,000			536,835,000	526,102,000	523,391,000
INTANGIBLE ASSETS, net	197,362,000	205,256,000				197,362,000			205,256,000	214,673,000	147,363,000
Accounts payable	21,969,000	32,895,000				21,969,000			32,895,000	24,470,000
Total comprehensive income (loss), net of tax	1,237,000	-1,140,000	4,693,000	-520,000	-102,000	1,732,000	-622,000	4,071	2,931	-1,471,000	-5,184,000
Scenario, Adjustment [Member]
Errors in prepaid assets	1,200,000					1,200,000
Errors in depreciation						400,000
Net sales		-5,000	-45,000	-45,000	65,000		20,000	-25,000	-30,000	-110,000	130,000
Cost of sales		116,000	80,000	0	-33,000		-33,000	47,000	163,000	365,000	779,000
Gross profit		-121,000	-125,000	-45,000	98,000		53,000	-72,000	-193,000	-475,000	-649,000
Total operating expenses		30,000	214,000	88,000	-17,000		71,000	285,000	315,000	331,000	297,000
Operating income		-151,000	-339,000	-133,000	115,000		-18,000	-357,000	-508,000	-806,000	-946,000
Total other income (expenses)		15,000	15,000	-131,000	-31,000		-162,000	-147,000	-132,000	-138,000	806,000
Income (loss) before taxes		-136,000	-324,000	-264,000	84,000		-180,000	-504,000	-640,000	-944,000	-140,000
Income tax expense (benefit)		-1,000	148,000	102,000	-31,000		71,000	219,000	218,000	345,000	51,000
Net income (loss)		-137,000	-176,000	-162,000	53,000		-109,000	-285,000	-422,000	-599,000	-89,000
Net cash provided by (used in) operating activities									-599,000	-231,000	105,000
Net cash provided by (used in) investing activities									599,000	0	126,000
Net cash provided by (used in) financing activities									0	0	0
Cash and cash equivalents											231,000
Accounts receivable, net of allowances		-180,000							-180,000	-110,000	-1,685,000
Inventories		178,000							178,000	17,000
Prepaid expenses and other		-504,000							-504,000	-269,000	-23,000
Total current assets		-506,000							-506,000	-362,000	-1,477,000
PROPERTY, PLANT AND EQUIPMENT-AT COST, net		-618,000							-618,000	-259,000	-305,000
OTHER ASSETS		-950,000							-950,000	-651,000	-348,000
GOODWILL		179,000							179,000	179,000	179,000
DEFERRED INCOME TAXES, long term		636,000							636,000	418,000	73,000
Total assets		-1,259,000							-1,259,000	-850,000	-1,781,000
Accrued liabilities		-110,000							-110,000	-70,000	-1,652,000
Current portion of contingent payments		-5,423,000							-5,423,000
Total current liabilities		-5,533,000							-5,533,000	-122,000	-1,652,000
Contingent consideration, net of current portion		5,333,000							5,333,000
Total liabilities		-200,000							-200,000	-122,000	-1,652,000
Additional paid-in capital		91,000							91,000
Retained earnings		-1,150,000							-1,150,000	-728,000	-129,000
Total stockholders' equity		-1,059,000							-1,059,000	-728,000	-129,000
INTANGIBLE ASSETS, net										-175,000	97,000
Accounts payable										-52,000
Total comprehensive income (loss), net of tax		-137,000	-176,000	-162,000	53,000		-109,000	0	-422,000	-599,000	-89,000
Scenario, Previously Reported [Member]
Net sales		94,065,000	88,195,000	88,616,000	83,579,000		172,195,000	260,390,000	354,455,000	342,026,000	221,787,000
Cost of sales		46,534,000	43,277,000	43,686,000	41,097,000		84,783,000	128,060,000	174,594,000	173,037,000	95,829,000
Gross profit		47,531,000	44,918,000	44,930,000	42,482,000		87,412,000	132,330,000	179,861,000	168,989,000	125,958,000
Total operating expenses		43,796,000	38,066,000	43,356,000	41,195,000		84,551,000	122,617,000	166,413,000	161,895,000	128,920,000
Operating income		3,735,000	6,852,000	1,574,000	1,287,000		2,861,000	9,713,000	13,448,000	7,094,000	-2,962,000
Total other income (expenses)		-1,489,000	-1,985,000	-1,660,000	-1,934,000		-3,594,000	-5,579,000	-7,068,000	-7,737,000	-2,320,000
Income (loss) before taxes		2,246,000	4,867,000	-86,000	-647,000		-733,000	4,134,000	6,380,000	-643,000	-5,282,000
Income tax expense (benefit)		-3,324,000	-176,000	-13,000	221,000		208,000	32,000	-3,292,000	31,000	188,000
Net income (loss)		-1,078,000	4,691,000	-99,000	-426,000		-525,000	4,166,000	3,088,000	-612,000	-5,094,000
Net cash provided by (used in) operating activities									25,280,000	26,883,000	11,497,000
Net cash provided by (used in) investing activities									-17,047,000	-22,238,000	-176,360,000
Net cash provided by (used in) financing activities									-14,016,000	-6,286,000	142,338,000
Cash and cash equivalents											23,508,000
Accounts receivable, net of allowances		62,148,000							62,148,000	47,791,000	48,588,000
Inventories		61,056,000							61,056,000	55,062,000
Prepaid expenses and other		5,975,000							5,975,000	7,554,000	9,826,000
Total current assets		152,228,000							152,228,000	141,516,000	159,238,000
PROPERTY, PLANT AND EQUIPMENT-AT COST, net		67,208,000							67,208,000	62,650,000	55,915,000
OTHER ASSETS		4,876,000							4,876,000	5,559,000	10,707,000
GOODWILL		360,294,000							360,294,000	355,458,000	308,912,000
DEFERRED INCOME TAXES, long term		9,767,000							9,767,000	11,007,000	39,198,000
Total assets		800,150,000							800,150,000	791,584,000	721,769,000
Accrued liabilities		16,762,000							16,762,000	16,426,000	18,722,000
Current portion of contingent payments		16,341,000							16,341,000
Total current liabilities		72,286,000							72,286,000	63,437,000	55,422,000
Contingent consideration, net of current portion		51,080,000							51,080,000
Total liabilities		262,256,000							262,256,000	264,754,000	198,249,000
Additional paid-in capital		508,263,000							508,263,000
Retained earnings		32,651,000							32,651,000	29,563,000	30,175,000
Total stockholders' equity		537,894,000							537,894,000	526,830,000	523,520,000
INTANGIBLE ASSETS, net										214,848,000	147,266,000
Accounts payable										24,522,000
Total comprehensive income (loss), net of tax		-1,003,000	4,869,000	-358,000	-155,000		-513,000	4,356	3,353	-872,000	-5,095,000
Restatement Adjustment [Member]
Contingent consideration liabilities reclassified as long term from current	$5,400,000					$5,400,000